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Why a zebra?  
 
The phrase ”when you hear hoof beats, think horses, not zebras” is often told to medical 
students during their clinical training. In this context, the term “zebra” is used to explain a 
rare disease or condition, such as a pheochromocytoma or a paraganglioma. Doctors in spe 
are often taught to assume that the simplest explanation usually is the best and that common 
diseases are what physicians should expect to encounter. Therefore, patients can experience 
a delay obtaining the correct diagnosis and proper treatment for a rare disease if doctors 
forget that zebras exist and assume horses every time hoof beats are heard. In order to 
increase neuroendocrine tumor (NET) awareness, the Worldwide NET Cancer Awareness 
Day (Nov 10
th
) has chosen the zebra and the zebra striped ribbon. 
 
 
 
Dedicated to cancer patients 
  
The zebra striped NET Cancer Awareness Day ribbon. 
© Carcinoid Cancer Foundation 
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ABSTRACT 
Pheochromocytomas (PCC) and abdominal paragangliomas (PGL), collectively denoted PPGL, 
are neuroendocrine tumors (NET) with a highly diverse genetic and molecular etiology, arisen 
in the adrenal medulla and abdominal paraganglia respectively. The tumors often cause 
cardiovascular symptoms due to the high production of catecholamines, and malignancy occurs 
in 10% of the PCCs and 30% of the PGLs. The genetic background of the PPGL disease 
constitutes of hereditary mutations in a growing list of susceptibility genes, although a large 
subset of the sporadic tumors still has an unknown etiology. This thesis work aimed to further 
characterize the genetic and molecular background of PPGL, in order to contribute to better 
diagnosis, prognosis and treatment for the patients.  
In the first study we investigated the role of susceptibility gene promoter methylation in PPGL. 
By studying the gene expression and assessing the promoter methylation levels, it was found 
that the VHL gene is epigenetically inactivated in PPGL. Subsequently, in order to investigate 
the established susceptibility genes in a large cohort, we used a targeted sequencing approach in 
the second study and found that next-generation sequencing is fast and cost-effective method for 
mutational screening of PPGL. Additionally, the NF1 gene was found to be the most frequently 
mutated gene, and in the third study we used the NF1 mutational status obtained in the second 
study to investigate if immunohistochemistry could be used as a screening tool for NF1 
mutations. We found a strong sensitivity but poor specificity for the method and therefore 
recommend genetic screening as the most efficient tool to identify NF1 patients. The list of 
PPGL susceptibility genes is constantly growing, and one of the latest genes verified is the 
HRAS gene. In the fourth study we screened a large cohort of PPGL for mutations in the HRAS 
gene and compared with the overall gene expression obtained using a mRNA microarray 
approach. Taken together with HRAS mutations in the literature, the overall HRAS mutation 
frequency was calculated to 5.2% in PPGL. The gene expression profiling showed that the 
HRAS mutated tumors clustered together with the NF1- and RET-mutated tumors that are 
associated with activation of kinase pathways. With the mutational information obtained in the 
second study, we were able to screen PCCs without known genetic drivers. In the fifth study, 
these tumors underwent whole-exome sequencing, detecting recurrent mutations in the KMT2D 
gene. After screening of a verification cohort, a total KMT2D mutation frequency of 14% was 
established. In the sixth study we screened PGLs for mutations in the KMT2D gene. All PGLs 
exhibited wild-type however KMT2D gene over-expression was observed in PGLs compared to 
normal adrenal samples. These results would imply dysregulation of methyltransferase as a 
novel disease mechanism in PPGL. In summary, the studies included in the thesis have 
increased the knowledge of the genetic and molecular background of PPGL. The results may 
therefore in the long run contribute to better diagnosis, prognosis and development of future 
treatment options for the patients. 
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POPULÄRVETENSKAPLIG SAMMANFATTNING 
Feokromocytom (PCC) och paragangliom (PGL) (tillsammans förkortade PPGL) är ovanliga, så 
kallade neuroendokrina tumörer som har en synnerligen varierad genetisk bakgrund där ungefär 
en tredjedel av tumörerna har visats bero på ärftliga mutationer i kända gener. Orsaken till 
tumöruppkomst i den resterande andelen patienter vet man fortfarande mycket lite om. PCC 
uppkommer i binjuremärgen och PGL i paraganglierna som är ansamlingar av neuroendokrina 
celler i anslutning till det autonoma nervsystemet. Tumörerna orsakar ofta hjärt- och 
kärlrelaterade symtom på grund av att de ofta producerar stora mängder av stressrelaterade 
hormoner, mestadels adrenalin och noradrenalin. De flesta tumörerna är godartade, men ungefär 
5% av PCC och ca 30% av PGL är elakartade i den meningen att de ger upphov till spridd 
sjukdom (metastaser). Syftet med avhandlingen i sin helhet har varit att vidare klarlägga den 
genetiska och molekulära bakgrunden till PPGL, och detta genom de sex ingående delarbetena. 
I den första studien undersökte vi vilken roll epigenetik och närmare bestämt promotor-
metylering har i tumörutvecklingen av PPGL. Graden av promotor-metylering bestämdes med 
hjälp av pyrosekvensering för 11 av de sjukdomsorsakande PPGL-generna, och av dessa var 
särskilt VHL-genen högt metylerad. Efter att ha korrelerat uttrycket av VHL-genen med dess 
metyleringsnivåer kunde vi konstatera att genen är inaktiverad av denna metylering och att det 
därför kan vara en nyupptäckt orsak till tumörutveckling i PPGL.  
Genom att därefter använda oss av en ny typ av riktad sekvenseringsteknik (nästa generationens 
sekvensering) kunde vi i den andra studien i avhandlingen undersöka alla då kända 
sjukdomssorsakande gener för PPGL med en och samma metod. Vi kunde konstatera att NF1 
var den gen som var mest frekvent muterad och att metoden vi designat var en snabb och 
kostnadseffektiv teknik att använda för att eftersöka mutationer i denna tumörgrupp.  
I den tredje studien undersökte vi om immunhistokemi kunde användas för att hitta mutationer i 
NF1-genen, då denna gen är mycket svårsekvenserad på grund av sin längd. NF1-mutationer ger 
upphov till NF1-syndromet som är ett tumörsyndrom i vilket PCC ingår som delfenomen. 
Eftersom vi sedan studie II kände till vilka tumörer som hade NF1-mutation kunde denna data 
jämföras med immunhistokemiska färgningar. Det visade sig att sensitiviteten var god men då 
specificiteten inte var godtagbar rekommenderar vi i denna studie att sekvensering tillsammans 
med klinisk undersökning trots allt är den mest pålitliga metoden för att identifiera patienter 
med NF1-syndromet.  
Listan på sjukdomsorsakande gener som är involverade i PPGL växer ständigt då nya gener 
upptäcks allt eftersom. En av de gener som senast verifierades som en orsak till PPGL är HRAS-
genen som vi därför undersökte i en stor kohort i studie fyra. Vi använde också en metod där 
uttrycket av ca 29000 gener kunde mätas och jämförde detta med det mutationsdata vi hade fått 
fram. Den totala frekvensen av HRAS-mutationer i vår och alla tidigare publicerade artiklar som 
berört ämnet, beräknades till 5,2%. Det konstaterades också att de PPGL som hade HRAS-
mutation samlades tillsammans med NF1- och RET-mutanterna i ett kluster med liknande 
genuttrycksprofil associerade med aktiv kinas-signalering. 
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Då vi i studie två analyserat alla då kända sjukdomsorsakande gener, kunde vi välja ut 15 PCC 
där ingen mutation kunnat identifieras för att undersöka alla geners kodande regioner (hel-
exomsekvensering) i dessa tumörer. Syftet med den femte studien var att upptäcka eventuella 
nya gener som är involverade i utvecklingen av PCC. Vi fann att KMT2D, en gen som kodar för 
ett så kallat metyltranferas var upprepat muterad i tumörerna, och tillsammans med resultaten av 
en riktad KMT2D-screening bland PCC, upptäckte vi en mutationsfrekvens på 14%. I 
uppföljande experiment kunde vi därefter konstatera att en störd reglering av metyltransferaser 
kan vara en ny potentiell sjukdomsmekanism för PPGL.  
I den sjätte studien undersökte vi om det fanns PGL som också hade mutationer i KMT2D-
genen. Med hjälp av både hel-exomsekvensering och riktad KMT2D-sekvensering konstaterade 
vi att inget av de 13 undersökta PGL hade någon mutation. Däremot fann vi att genen var 
överuttryckt i PGL jämfört med normala binjurar och föreslår därför en onormal reglering av 
metyltransferaser även i PGL.  
Sammanfattningsvis har avhandlingens sex ingående studier givit en ökad förståelse för den 
genetiska och molekylära bakgrunden till PPGL. Resultaten kan därför i framtiden bidra till 
bättre diagnosticering, prognos och utveckling av behandlingsalternativ för patienterna som 
drabbats av denna sjukdom. 
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INTRODUCTION 
THE NORMAL ADRENAL GLAND AND PARAGANGLIA 
Historical perspective 
“Nature makes, nor does nothing in vain or inconsiderately, much less does she appoint a 
noble animated part, only to fill a space, which she might have filled by making the kidney a 
little bigger.” – Thomas Bartholin 1668 in a response to Adriaan van den Spiegel who 
believed that the only function of the adrenal glands was to occupy the space between the 
kidneys and the diaphragm (1,2). 
The first description of the adrenal glands may be found in the Bible. In the context of guilt 
offering, the King James translation of Leviticus 7:4 reads: “And the two kidneys, and the fat 
that is on them, which is by the flanks, and the caul that is above the liver, with the kidneys, it 
shall he take away”. It can be argued that the fat on the kidneys described here refers to the 
adrenal glands, but the location - by the flanks and the word for fat make this statement 
somewhat dubious. However, the first detailed illustrations and less debatable description of 
the human adrenal glands can be found at copper plates made by Bartholomeo Eustachio in 
1552 (Figure 1) ((3), reviewed in (2)). He labeled these glands “glandulae renibus 
incumbentes” which is translated to “glands lying on the kidneys”. With this, Eustachio 
disputed the famous anatomist Andreas Vesalius who had neglected to describe adrenal 
glands in his reports of dog kidneys (4). The work “Opuscula Anatomicae” by Eustachio was 
forgotten in the archives of the Vatican library until 1714 when the physician of Pope 
Clement XI, Lancisius Giovanni Maria discovered and republished them ((5), reviewed in 
(1)) as he appreciated the correctness of the plates. Furthermore, Eustachio was able to 
describe additional adrenal tissue close to the aortic bifurcation (4). This extra-adrenal tissue 
is now known as the organ of Zuckerkandl and can be found close to the inferior mesenteric 
artery or at the aortic bifurcation (Figure 2). 
In the beginning of the 19
th
 century, Albert von Kölliker was able to make a distinction 
between the adrenal cortex and medulla and also described the histological and physiological 
features of the glands, using a microscope with achromatic lenses ((6), reviewed in (1)). In 
1855, the English physician Thomas Addison observed and described a rare and fatal disease 
which was characterized by skin pigmentation, weakness and cardiac insufficiency. The 
disease was later named after him since he understood that the effects of the disease were 
related to the “suprarenal capsule” ((7), reviewed in (1)). The finding of norepinephrine (NA) 
as a secretory product from the adrenal medulla was an important break-through in the 
adrenomedullary research and many researchers were involved in the discovery. A notable 
researcher in this area was the 1970 Nobel Prize laureate, Ulf Svante von Euler at KI who 
was recognized for his discoveries of prostaglandin in 1935, piperidine in 1942 and 
norepinephrine in 1946 (2,8). 
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Figure 1.  
The first description of the adrenal gland.  
Photocopy of the original copper plate (Tabulae II) of Bartholomeo Eustachio 
from 1552 in Opuscula Anatomicae, published by Lancisius in 1714 and by 
Tagliani in 2009 (5,1). The figure is republished with permission.  
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Anatomy, histology and physiology of the adrenals 
The adrenal glands are triangular-shaped endocrine organs, normally located on top of the 
kidneys in the retroperitoneal space (Figure 2). The name adrenal comes from the Latin ad 
meaning “near/close to” and ren meaning kidney. They usually weigh 5 grams and are 
composed of the adrenal cortex and the adrenal medulla (9). The cortex consists of three 
layers; zona glomerulosa, zona fasciculata (ZF) and zona reticularis (ZR) with important 
endocrine functions as they produce and secrete aldosterone, cortisol and androgens 
respectively (Figure 3). The adrenal medulla (AM), as of special interest in this thesis, weighs 
on average 0.43 grams each (9) and its main functional component is the chromaffin cells that 
produce the catecholamines norepinephrine/noradrenaline (NA), epinephrine/adrenaline (A) 
and dopamine (DA) (Figures 3 and 4). Catecholamines are peptide hormones synthesized 
from the amino acid tyrosine through L-dopa to dopamine. The enzyme dopamine beta 
hydroxylase (DBH) converts dopamine to NA and phenylethanolamine N-methyltransferase 
(PNMT) converts NA to A (10,11) (Figure 4). Circulating catecholamines excite fight-or-
flight responses in the body with visceral manifestations including for instance affection of 
blood pressure through regulation of cardiac output and peripheral vessel resistance. Other 
manifestations are tachycardia, affection of muscle tonus, fatty acid metabolism and sweating 
(10,12). The adrenal medulla and the paraganglia
1
 are parts of the sympathetic nervous 
system and are located in the adrenal glands and lengthwise the aorta (Figure 2) (13,14).  
  
                                                 
1
 The word ganglia refers to sympathetic nerve cell clusters. 
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Figure 2.  
Anatomical outline of human chromaffin cells and its adjacent tissues.  
Chromaffin cells (black text) are derived from the embryological neuroectoderm within 
the paraganglia and the medulla of the adrenal glands. The organ of Zuckerkandl is also 
called corpora paraaortica and is one of the ganglia prevertebralia which can be located at 
the origin of IMA (as in this figure) or closer to the aortic bifurcation.  
The figure is inspired by and modified from Lips et al. (14). 
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Figure 3.  
Immunohistochemical picture of a normal adrenal gland.  
The slide is stained with an anti-NF1 antibody (1:100) showing strong immunoreactivity 
in zona fasciculata (ZF) and zona reticularis (ZR) of the adrenal cortex as well as absent 
staining of the adrenal medulla (AM). The image is magnified x40 and adopted and 
modified from the supplementary material of Paper III. 
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Figure 4.  
The synthesis of catecholamines and metanephrines. 
Arrows indicating the chemical reactions resulting in conversions between the molecules, 
catalyzed by the enzymes entitled in italics adjacent to the arrow. All molecules contain a 
phenol (C6H5OH) ring. Tyrosine is also a precursor for the hormone thyroxine of the 
thyroid gland and the pigment melanin.  
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CANCER AND ITS GENETIC AND MOLECULAR BACKGROUND  
Nomenclature 
”In reality, a mutually agreeable definition of cancer is not possible.” – Douglas Green and 
Gerard Evan, 2002 (15). 
All cancers are diseases of abnormal gene function, but only a minority (5-10%) is 
hereditary
2
. Abnormal gene function is due to one or more genetic and/or epigenetic 
aberration(s) with reference to the healthy (normal) genome. The human genome is coded by 
four different nucleotides
3
 linked into a double stranded chain with a total length of 
approximately 3 billion base pairs (16) equals 2-3 meters if stretched out (17), or 3 Gigabytes 
of information (18). Fortunately, via histones the DNA is structured into 23 chromosomes 
that are located in almost
4
 every cell nucleus in the human body. The information of the 
dynamic DNA molecule (genome) is divided into exons and introns where a large proportion 
of the DNA is transcribed to RNA (transcriptome). Only a small fraction of the RNA is 
subsequently translated into proteins and the assembly of proteins coded from DNA via 
mRNA is often referred to as the central dogma. Which genes that are expressed differ from 
cell to cell and changes over time, regularly via epigenetic variations (methylome). A gene 
often contains both exons and introns and can be of different length, function and 
organization.  
A tumor is a cell mass that grows in an uncontrolled manner and can be either benign (grow 
locally within a capsule) or malignant (invade neighboring tissues and/or metastasize). The 
minority of malignant tumors are called cancers. Highly malignant cancers have lost many of 
the abilities of their fully differentiated normal precursor cell, making them 
“undifferentiated”. (19–22). 
Cancer genetics 
Genetic aberrations can be acquired (sporadic tumors) and caused by environmental factors
5
 
that causes damage to the genes, or constitutional/germ-line (hereditary tumors) that are 
typically passed from a parent to a child. One single genetic abnormality alone is rarely 
enough for the development of malignant disease, and cancer is therefore often described as a 
multistep process of several alterations in one or more of different classes of genes (24). 
                                                 
2
 As mentioned under “etiology”; PPGL carry the highest level of heritability of all human tumors 
(25-40%). 
 
3
 Nucleobases of the human DNA: Adenine, Guanine, Cytosine and Thymidine. 
 
4
 Some cells of the human body do not harbor a nucleus. Erythrocytes are the most common example 
and consequentially do not contain any DNA. 
 
5
 The main environmental factors that can damage DNA and contribute to cancer include cigarette 
smoking, diet, infections and radiation (23).  
 
22 
 
During the development of a tumor, its cells progressively obtain features that give them 
growth-, survival- and spreading advantages over fully differentiated normal cells
6
. The 
multistep process can be seen as an evolutionary process within the cancer cell and often 
takes place during years or decades. These advantages or “hallmarks” of a full blown cancer 
with metastatic potential have been well described by Hanahan et al. (19,20) and include ten 
capabilities of the cancer cell as visualized in Figure 5; ability to escape cell death, 
independence of growth signals, desensitization of anti-growth signals, unlimited potential to 
replicate, continued angiogenesis and the capability to metastasize and invade other tissues 
(19), deregulation of cellular energetics
7
 (glycolysis, aerobic oxidation), escaping immune 
destruction, tumor-promoting inflammation and genome instability and mutations (often in 
DNA repair mechanisms) (20). The genetic alterations that could give rise to these 
capabilities of the cancer cell (driver events) include somatic and/or constitutional mutations 
in key genes (oncogenes, tumor suppressor genes and DNA repair genes), chromosomal 
losses, gains or rearrangements (19,20,24,26), and/or epigenetic modifications (DNA 
methylation and/or histone alterations) (27). 
In addition, during the development of a cancer cell, multiple genome aberrations occur that 
have no obvious driver role. These are regarded as passenger events. A passenger event has 
by its definition “no direct or indirect effect on the selective growth advantage of the cell” 
(28) but could hypothetically contribute to genetic instability which in turn could lead to other 
alterations of importance. Driver mutations are often defined based on the recurrence rate and 
existence of hotspot mutations
8
. To be able to find out whether a non-hotspot mutation is 
biologically relevant, functional assays often need to be performed (29). Besides functional 
assays, computational methods (in silico) can be used where different software algorithms 
calculate the probability of an amino acid change to have biological implications (30). In 
Papers II and V (31,32), three different algorithms has been used to predict the pathogenicity 
of the novel variants/mutations found; PolyPhen2 (33) (Paper II and V), MutationTaster (34) 
(Paper II) and CHASM (35) (Paper V), but several other prediction algorithms are frequently 
used, such as SIFT (36) and Condel (37) to name a few. The main difference between the 
algorithms used in Paper II and V is that MutationTaster can predict the pathogenicity of 
suspected splice-site mutations while the CHASM algorithm uses a class of driver mutations 
obtained from COSMIC and a class of cancer specific passenger mutations and gives a scored 
based on a statistical comparison. Finally, Polyphen2 predicts the impact of amino acid 
substitutions by physical and comparative considerations. 
                                                 
6
 The acquiring of capabilities of a cancer cell can be likened to Darwinian evolution where an 
obtained capability might favor in the natural selection (22).  
 
7
 The cancer cell characteristic of deregulation of cellular energetic has been described in the follow-
up review by Hanahan et al 2011 (20), but was originally described in Science in 1956 by Otto 
Warburg (25) who found that cancer cells can limit their need of energy metabolism (referred to as the 
Warburg effect).   
 
8
 A mutational hotspot is a region where mutations are observed with higher frequency. 
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Tumor biology and driver mutations 
The human body consists of around 4x10
13
 cells (38) which constantly grow, divide and die 
in a balanced process during the life of the individual. The life span of the cell is regulated in 
the cell cycle and the apoptotic process (programmed cell death) attempts equilibrium 
between dividing/proliferating and dying/apoptotic cells (39). Somatic cells are proliferating 
through mitosis when they duplicate their DNA which could be completed in a couple of 
hours. In the cell cycle, where these processes are controlled, a number of phases and 
checkpoints are present when the DNA is controlled for errors. If any inaccuracies are 
present, the cell will be prompted to undergo apoptosis. Any disruption in the various aspects 
of the cell cycle could be critical for the cell and might lead to cancer (40). 
Figure 5.  
Ten hallmarks of cancer.  
The figure is adopted and modified from Hanahan and Weinberg 2011 (20) and reprinted 
with permission under personal Elsevier user license. 
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Genetic alterations can be divided into mutations at the DNA level and structural 
translocations and losses or gains at the chromosomal level. Loss of heterozygosity (LOH) 
means that one of the two constitutional DNA copies is lost which can provide the “second 
hit” of Knudson two-hit hypothesis9 (42) (Figure 6). Importantly, LOH may be copy neutral 
(CN-LOH) meaning that no net change in the copy number
10
 occurs e.g. by duplication of the 
remaining copy. CN-LOH cannot be detected by regular comparative genomic hybridization 
(CGH) techniques or qRT-PCR, instead FISH or SNP-array based techniques are required 
(45,46).  
Mutations in its turn may be divided into single nucleotide base substitutions
11
, deletions and 
insertions where the last two mutation types often lead to a frameshift mutation (28). 
Deletions and insertions can also affect a triplet of base pairs resulting in an addition or loss 
of one amino acid in the protein (in-frame). Mutations can also be silent or synonymous 
meaning that they do not change the amino acid sequence of the protein, or change an amino 
acid to another that harbor similar properties as the original. In the same way as passenger 
mutations can lead to genetic instability and through that cause other aberrancies, also silent 
or synonymous mutations have been shown to be able to act in a similar manner (47). An 
example of this has been shown with a synonymous mutation in the CFTR gene that causes 
an aberrant mRNA splicing in a patient with cystic fibrosis (48). The mutational driver events 
that contribute to tumor development most often target three main classes of genes, 
previously referred to as tumor suppressor genes (TSG), oncogenes and DNA repair genes. 
Tumor suppressors are normally antagonizing cell growth, proliferation and survival while 
oncogenes support the same processes. DNA repair genes are coding for proteins that are able 
to restore errors in replication and breaks in the DNA strand, often within the process of the 
cell cycle when the cell is about to proliferate. In order for an oncogene to cause a tumor-
promoting effect on the cell, a gain-of-function mutation (GOF) is normally needed to cause 
over-activation of the gene (49). For most DNA repair genes and some tumor suppressor 
genes, biallelic inactivating mutations in accordance with Knudson´s two hit hypothesis is 
usually seen and needed for the gene to lose its tumor developmental breaking effect 
(26,41,42) (Figure 6).  
                                                 
9
 Since a tumor suppressor gene is represented on two alleles of the chromosomes, Knudson´s two hit 
theory explains that both copies of the gene need to be inactivated in order for the gene to lose its 
function (41,42). However, some genes do need two intact alleles for proper function and those 
haploinsufficient genes can contribute to tumor development with only one allele inactivated (43,44) 
(Figure 6E and F). Tumor suppressor genes (TSGs) are often haploinsufficient. 
 
10
 Copy number refers to the quantity of alleles at a specific genomic site. 
 
11
 Further functional categorization of single nucleotide substitutions divides them into nonsense-, 
missense or silent mutations. Nonsense mutations code for a stop, often resulting in a truncation of the 
protein. Missense mutations code for an altered amino acid and silent mutations code for the same 
amino acid resulting in no protein alteration.  
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Epigenetics 
The latin word epi means above and refers to something that happens above or on top of the 
DNA and without modification of the underlying nucleotides (Figure 6). Epigenetic 
mechanisms represent the control machinery that determines gene expression and its activity 
in the cell. The epigenetic machinery is highly involved in the cell differentiation processes 
that produce diverse subpopulations of cells from stem cells. If the machinery in some way is 
disrupted or dysregulated, it can contribute to tumor development in general (27), and to the 
development of PPGL (50–54). Epigenetic modifications can be divided into two different 
classes of modification mechanisms; histone regulation and DNA methylation.  
Small octamer proteins called histones that provide efficient packing of DNA, also play an 
important role in gene regulation via acetylation, methylation and/or phosphorylation at 
different sites. Here, histone acetylation is the most described modification which is generally 
associated with activation of gene transcription. Cancers have been shown to display changes 
in their histone modifying enzymes compared to normal cells. (55,56) 
DNA methylation is a well described mechanism for gene expression control. Anywhere 
throughout the genome where a cytosine nucleobase is followed by a guanine nucleobase (a 
CpG dinucleotide) the DNA can be methylated when a methyl group (CH3) covalently binds 
to the cytosine residue. Particularly CpG rich regions along the genome is referred to as CpG 
islands and are often located within regulatory elements such as promoter regions of several 
genes. It is commonly observed that cancer cells lose their normal levels of methylation 
across the genome which could contribute to genetic instability and to tumor development 
(27). Both hypo- and hypermethylation can be seen. Hypermethylation
12
 of CpG islands 
within TSG promoter areas can provide the second hit of Knudson two-hit hypothesis and 
hence contribute to tumor development (27,44,58) (Figure 6). Moreover, gene- and histone 
methylation is involved in the phenomenon of genomic imprinting
13
, whereby the expression 
from a particular gene occurs from a single allele (61,63).  
  
                                                 
12
 Promoter hypermethylation is an increase in methylation, often defined as >10% of an average of 
CpG residue methylation at a specific site (57), but the cutoff can vary between genes dependent of 
the silencing effect and intrinsic methylation levels (52). 
 
13
 All somatic cells contain two copies (alleles) of the genome. These are inherited with one copy from 
each parent. Through epigenetic processes, a hypothesis of “parental conflict” (59) have made 
approximately 1% (or more) of all genes in mammals “imprinted” (60,61), resulting in a specific 
mono-allelic gene expression from only one of the parents. On the other hand, loss of imprinting of 
specific genes could result in diseases, such as syndromes of Prader-Willi/Angelman, Beckwith-
Wiedemann or Silver-Russell (62). 
Two PPGL-related examples are the maternally imprinted SDHD and SDHAF2 genes that give 
significantly different PPGL penetrance depending on if the mutations are paternally or maternally 
inherited (Table 1). 
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Figure 6. Genetic inactivation and the Knudson two hit model.  
The left column indicates 6 germ-line allele scenarios (A-F) of a specific gene. A blue 
DNA spiral indicate inactivated alleles and red spirals are functional alleles. The middle 
column shows a 1
st
 hit and inactivation of one allele in 3 different situations (A, C and D). 
The right column shows possible outcomes of the gene alleles in tumor development.  
A and B: shows the Knudson two-hit model when an initial mutation leads to complete 
gene inactivation during tumor development.  
C and D: describes two different situations of complete gene inactivation from healthy 
germ-line DNA when in C, the mutation is followed by gene silencing through an 
epigenetic event (histone acetylation or gene promoter methylation) and in D, an initial 
event of epigenetic silencing is followed by another event of either LOH or another 
epigenetically silenced allele.  
E and F: describes that haploinsufficient genes (often TSGs) can contribute to tumor 
development with only one allele inactivated either due to a somatic (E) or a germ-
line/inherited event (F). The figure is inspired by and modified from Balmain et al (44). 
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PHEOCHROMOCYTOMA AND PARAGANGLIOMA 
“Despite being predominantly benign tumours, pheochromocytomas and paragangliomas 
have substantially advanced our understanding of cancer biology.” – Patricia L.M. Dahia, 
2014 (64).  
Due to the excessive secretion of fight-and-flight hormones, the dramatic clinical presentation 
of pheochromocytomas and abdominal paragangliomas has fascinated physicians and 
researchers for ages. The disease is rare, with an annual incidence estimated to 0.8 in 100,000 
person-years (65,66) but it is nevertheless a particularly well-described disease. The term 
pheochromocytoma was first used in 1912 by Ludwig Pick after Heinrich Poll a few years 
earlier had introduced the term “pheochrome” to describe the dark color produced during the 
“chromaffin reaction” when tumor tissue was immersed in chromium salts. The chromaffin 
cell got its name from this reaction by Alfred Kohn in 1902. (2) 
Chromaffin cells in the adrenal medulla can give rise to pheochromocytomas (PCC). These 
neural-crest derived chromaffin cells can also be found extra-adrenally within the 
sympathetic ganglia and give rise to abdominal paragangliomas (PGL) (67) (Figure 2). 
Collectively PCC and PGL are abbreviated PPGL. Paragangliomas can, however, also occur 
in cells of non-chromaffin origin in supra-diaphragmatical chemoreceptors and in 
parasympathetic ganglia in the head and neck (Figure 2) (65). These neoplasms are usually 
unable to secrete catecholamines (68) and are often referred to in the literature as “head and 
neck paragangliomas”. However, this entity will not be discussed further in this thesis.  
PPGLs occur in 2-5 patients per million per year (69,70), which gives approximately 55,000 
new PPGL cases each year worldwide (71) although as many as 40% of PCC are only found 
at autopsy (65,66).  
An outdated rule of 10 was for long time used as a traditional ‘mnemonic’14 for the disease 
(10% bilateral, 10% extra-adrenal, 10% familial, 10% malignant), but latter advances in 
genetics and diagnosis have challenged the rule and made it obsolete (73,74). The proportion 
of malignant cases differs between PCC (5-10%) and PGL (30-33%) and is even higher in 
PGLs with a mutation in the SDHB-gene (52,73,75). Bilateral tumors are more common 
within PCC-related tumor syndromes (MEN2, vHL) and the ratio of PGL probably represent 
at least 15% of adult and 30% of childhood chromaffin tumors (73,76). Finally, at least 25% 
of the tumors are hereditary (31,73,77–79). Hereditary forms of the disease are found in 
patients of younger age, but a vast overlap with sporadic tumors is seen in this group (74).  
Clinical presentation 
PPGL can be discovered in patients in several ways, en passant as incidentalomas (80) or due 
to symptoms of catecholamine release. It is also possible to discover them due to symptoms 
                                                 
14
 A memory technique that aims to translate information into a form that is easier for the brain to 
grasp and remember. Short poems, memorable phrases or acronyms are often used with favorable 
results regarding long-term memory (72).  
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of local growth (81), but they can also be asymptomatic and only be found at autopsy 
(66,73,82). The clinical presentation may be highly variable and can also mimic other clinical 
conditions. Generally PPGL produce large amounts of mainly NA and A, sometimes up to 27 
times higher than normal (83). These excess levels may cause a wide array of paroxysmal 
symptoms with a classic triad of palpitations, headache and sweating that altogether can 
provide a specificity of 90% (84,85). The most common signs at presentation includes 
headaches, hypertension, tachycardia, diaphoresis (profuse sweating), pallor, anxiety and 
panic attacks (73,84). The estimated prevalence of PPGL in hypertensive patients ranges 
from 0.1 (86) to 0.6% (87–89). Unusual clinical manifestations of PPGL are hypotension, 
cardiac insufficiency and shock which could be explained by several coactive mechanisms 
(90–92) including less intravascular blood volume (73) sudden stop of catecholamine 
production due to tumor necrosis and/or desensitization of adrenergic receptors (93,94). 
Diagnosis 
Measurement of free metanephrines
15
 in blood is today the best tool and golden standard 
method for both detection and exclusion of the disease (Figure 4) (96–98). PPGLs have been 
shown to express different catecholamine profiles dependent on their genetic background 
(95); epinephrine levels are often increased in patients with MEN2 (83) and NF1 syndromes 
as well as a mutation in the TMEM127 gene, and decreased in tumors with VHL and SDHx 
mutations (tumors associated with genes in gene expression Cluster 1) (99). Dopamine levels 
are often increased in SDHx mutated tumors (100) while norepinephrine does not seem to be 
strongly correlated with the genetics of the tumor.  
PPGL may also be detected through a range of different radiological modalities and imaging 
studies should be initiated when there is a biochemical evidence of PPGL (95). Computed 
tomography (CT) is recommended as first-choice modality for PPGL (95,101,102) and MRI 
is recommended if metastatic PPGL is suspected, if the patient harbor a known germ-line 
mutation and if the radiation exposure for the patient should be restricted (95). To detect 
metastatic lesions, 2-deoxy-2-[fluorine-18]fluoro-D-glucose integrated with computed 
tomography (18F-FDG PET/CT) may be used, preferably for suspected SDHx-mutated PGLs 
(103). The (11)C-hydroxyephedrine (HED) PET/CT has also been shown to demonstrate 
good sensitivity and specificity for PPGL (104).  
The prevalence of malignancy in PPGL is fairly puzzling. It has long been cited as 10%, but 
has also been suggested to be between 5 – 26% depending on how malignancy is defined and 
underlying mutation (71,75,105,106) identified. As previously mentioned, 5-10% of PCC 
(107) and 30-33% of PGL are malignant (73). In an American cohort of 371 patients reported 
in 2010, 60% of PGL and 25% of PCC was found with metastatic disease (71). In addition, 
                                                 
15
 Metanephrines are metabolites of epinephrine/norepinephrine, specific markers of chromaffin 
tumors produced by the enzyme catecholamine O-methyltransferase (COMT). Normal sympathetic 
nerves lack this enzyme making these metabolites specific markers of chromaffin tumors. Moreover, 
the metabolites are produced and released independently of catecholamine release (Figure 4). (95) 
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like some other endocrine tumors, no molecular marker exists today for determining whether 
a PPGL is malignant. For the pathologist, the process of diagnosing PPGL therefore presents 
several challenges due to the difficulties of separating potentially malignant from benign 
cases. Since PPGL metastases have been seen up to 10-20 years after a “benign” diagnosis, 
lifelong follow-up is recommended. Currently, according to the WHO criteria, malignancy is 
defined only by the presence of (simultaneous) metastases (65). AFIP - another applied 
classification system for PPGL also identify metastatic disease as a diagnostic criteria for 
malignancy, but also recognize the prognostic value of histopathological features of the 
primary tumor such as local invasion, vascular invasion, mitotic activity and/or cellular atypia 
(13). Most often, malignant PPGL metastasize to lymph nodes, bone and lungs (64,105,108) 
but metastases have also been reported in the skin and breasts (105,109). Moreover, due to 
the location of the adrenal medulla and sympathetic trunk, adjacent organs like the liver, 
pancreas and kidneys may also be infiltrated (105).  
Etiology 
The genetic background of PPGL is remarkably diverse. Of all human tumors, PPGL carry 
the highest degree of heritability (25-40%) (64,73,78) and have therefore served as an 
important model to study general driver events for tumorigenesis. After year 2000, when 
Baysal et al. first identified an inherited mutation in a metabolic enzyme (SDHD) in a human 
tumor model (110), the list of PPGL susceptibility genes have been constantly growing. 
Heritable (constitutional) mutations in the NF1, RET and VHL genes have been known since 
1990-1993 (111–114) and constituted the basis for the rule of 10% of hereditary tumors back 
then (full gene names are provided in the summary below). In 2006, six PPGL susceptibility 
genes were known (NF1, RET, SDHB, SDHC, SDHD and VHL) and the PCC researcher 
Patricia LM Dahia hypothesized that “new pheochromocytoma susceptibility genes are likely 
to emerge in the next years.” (115). After 2006 until today, some 10-18 more genes – 
hereditary and somatic - have been discovered and proved to be disease causing for PPGL 
(Table 1) and the list is still growing. Mutations in germ-line DNA associated with familial 
forms of PPGL currently include the following genes: FH, EPAS1/HIF2α, MAX, NF1, RET, 
SDHA, SDHB, SDHC, SDHD, SDHAF2/SDH5, TMEM127 and VHL. In addition, a few other 
genes have been suggested to cause familial forms of PPGL including BAP1, EGLN1/PHD2, 
KIF1Bβ, MDH2, and MEN1 (116) however these have only been reported in a few patients in 
a limited number of reports. Some of the above mentioned genes have also been reported to 
be mutated in sporadic PPGL
16
, and in excess of these genes, mutations have been reported in 
the ATRX, BRAF, FGFR1, HRAS, IDH1, KMT2D, MET and TERT genes. In total, 25 genes 
are listed up to date, that in some way are associated with PPGL tumorigenesis. These genes 
and coupled tumor syndromes are briefly described below (alphabetical order) and 
summarized in Table 1.   
                                                 
16
 The neurofibromin 1 (NF1) gene is the most recurrently mutated gene in sporadic PPGL and was 
discovered both by Burnichon and Welander in 2012 (117,118).  
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Genes associated with hereditary predisposition for PPGL 
BAP1 
An inactivating germ-line mutation has been reported in the BRCA1-associated protein-1 
(BAP1) gene in a Danish family with melanoma and a PGL. With only one mutation found in 
one single case, it remains unclear if the mutation drives the development of the PGL; 
however somatic loss of the wild-type allele in the PGL could support the association. (119) 
BRAF 
The common (in various cancers) activating missense mutation c.1799T>A in exon 15 in the 
proto-oncogene B-RAF (BRAF), that leads to the alteration V600E has been reported in one 
single PCC (out of 85 screened PPGL) in one recent study (120). In PGL, a CpG island 
methylator phenotype (CIMP) has been shown to be associated with malignant behavior as 
well as young age at presentation (50). Therefore, another cohort of 53 PPGL had previously 
been screened for this mutation (50) since CIMP was shown to be linked to BRAF mutations 
in colorectal cancer (121). Additionally, in another study from our group that is accepted for 
publication (listed among the related publications), we screened 110 PCCs for the BRAF 
V600E mutation and found that all cases exhibited the wild-type sequence at that spot. Taken 
together, a total number of 361 PCCs have been screened for the BRAF V600E mutation to 
date, with only 1 (0.3%) single mutation found in one PCC (120). As of this, it must be 
concluded that the BRAF V600E mutation is a rare event in PCC.  
EGLN1/PHD2 and EGLN2/PHD1 
A germ-line mutation in the egl-9 family hypoxia-inducible factor 1 gene (EGLN1) (also 
called PHD2) was found in a patient with polycythemia and a PGL in 2008 (122). The gene 
encodes PHD2, a 2-oxoglutarate-dependent prolyl hydroxylase that has a key role in 
regulating HIFα subunits and thereby the expression of HIFα transcription factors (123), 
probably via accumulation of succinate that inhibits PHD activity (124). It is further 
hypothesized that the tumorigenesis of succinate dehydrogenase-deficient PPGL is linked to 
the inhibition of different prolyl hydroxylases that in turn can up-regulate HIFα targets and 
transcription factors. In a follow-up study that was published three years after the initial 
finding of an EGLN1 mutation, the authors screened 82 PGL patients and failed to find any 
mutation in EGLN1, EGLN2 or EGLN3 (123). However two additional novel germ-line 
EGLN1 (A228S) and EGLN2/PHD1 (S61R) mutations were recently reported in two patients 
with polycythemia and PPGL (125). Additionally, these novel EGLN1 and EGLN2 mutations 
were also introduced into a vector using site-directed mutagenesis, and over-expression of the 
mutants PHD1-S61R and PHD2-A228S were shown to give decreased effect on HIF2α-
induced transcriptional activity (125).  
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FH 
The fumarate hydratase (FH) gene encodes an enzyme in the Krebs cycle (as the other PPGL 
susceptibility genes IDH1, MDH2 and SDHx that encodes other Krebs cycle enzymes) and 
was found mutated in germ-line in a PCC patient for the first time in 2013 (126). Later, five 
additional germ-line FH mutations were found among 598 PPGL patients without mutations 
in other PPGL susceptibility genes, which equals a total frequency of 0.8% (127). Although a 
low mutation frequency, the authors found that multiple tumors and metastatic phenotype 
were significantly more frequent in patients with a germ-line FH mutation. Moreover, FH-
mutated tumors were also found to display a similar pattern of epigenetic deregulation as 
SDHB-mutated PPGL using immunohistochemistry (IHC) for evaluating 5-hmC and 2SC
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levels (127). 5-hmC was found low and 2SC was found high in FH-deficient samples 
implying a useful tool to predict FH-mutated tumors. The mutational results have been 
confirmed in subsequent studies (129) showing additional 2/71 FH-mutated PPGL. Mutations 
in the FH gene are associated with the Reed syndrome, a disease of multiple cutaneous and 
uterine leiomyomatosis, but no co-occurrence has been seen with PPGL.  
EPAS1/HIF2α 
Germ-line GOF mutations in the Hypoxia-inducible factor 2 subunit alfa (HIF2α or EPAS1) 
gene were found to cause a syndrome of PGL and polycythemia
18
 for the first time in 2012 
(130). This was also the first evidence of EPAS1 as a bona fide proto-oncogene. The EPAS1 
gene encodes the transcription factor HIF-2α which is involved in several cellular interactions 
as a part of the hypoxic response (131). The mutations found in the original study were 
somatic only (130), however an exon 9 EPAS1 mutation were subsequently found in germ-
line of a polycythemic patient who developed PPGL (132). Later, it was proposed that 
HIF2A-related PPGL are caused by postzygotic mutations in the EPAS1 gene causing 
mosaicism
19
 for the mutation in the adult (135). Besides PPGL, some patients with mutations 
in the EPAS1 gene have been reported with somatostatinoma (136) and it has also been found 
that GOF mutations in the gene cause an up-regulation of hypoxia-related genes, including 
EPO and cancer-related genes (136,137).  
                                                 
17
 5-hydroxymethylcytosine (5-hmC) is a DNA base (cytosine) containing a hydroxymethylgroup (to 
be compared with its precursor 5-methylcytosine which is the methylated form of cytosine) and its 
levels can be measured using IHC. S-(2-succinyl) cysteine (2SC) is a marker for global changes in 
protein succination (of fumarate) (128) and both 5-hmC and 2SC have been found altered in SDHB-
mutated PGL (126,127). 
 
18
 Gem-line mutations in both the EGLN1/PHD2 and the EPAS1/HIF2A genes seem to cause PGL and 
polycythemia (122,130). 
 
19
 Mosaicism is the presence of two or more distinct populations of cell lines within the same 
individual, that throughout early development can lead to genetic abnormalities (133). The Klinefelter 
syndrome (XXY) is an example of chromosomal mosaicism where some cells contain XY and some 
contain XXY chromosomes (134).  
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KIF1Bβ 
The Kinesin Family Member 1B (KIF1B) gene has two splice variants; KIF1Bα and KIF1Bβ 
where the latter was coupled to PPGL tumorigenesis in 2008 when two constitutional 
mutations were found in patients who developed PCC (138). Six months after publication of 
the original study, another germ-line KIF1Bβ mutation was reported (139). The KIF1Bβ gene 
located in chromosomal region 1p36 encodes a kinesin (Kinesin-like protein) and is thought 
to act as a TSG via a mechanism that allows neuronal progenitor cells to escape apoptosis 
(138). KIF1Bβ mutations are linked to the Charcot-Marie-Tooth disease type 2A (140), 
however no co-existence with PPGL has been reported.  
MAX 
Until date, PPGL is the only tumor form that is associated to mutations in the MYC-
associated factor X (MAX ) gene which was found in 2011 (141). A grand follow-up study 
established a germ-line mutation prevalence of 1.12% based on screening of 1,694 PPGL 
patients from 17 centers (142) for mutations in the MAX gene. PC12 cells, a commonly used 
rat pheochromocytoma cell line (used in Paper V) was shown in 1995 to only express a 
mutated form of MAX (143). The protein MAX is a known transcription factor that plays a 
role in regulation of transcription and apoptosis as well as promotion of cell differentiation 
(144,145). 
MEN1 
The involvement of the multiple endocrine neoplasia type 1 (MEN1) gene as a PPGL 
contributor is disputed (31,146,147). The gene was mapped to 11q13 in 1988 (148) and is 
known to cause multiple endocrine neoplasia type 1 (MEN 1) (149), an autosomal dominant 
disease involving hyperplastic and neoplastic lesions arising from the parathyroid, pituitary 
and pancreas with a penetrance reaching 100% with age (150). Many times, PCCs have been 
described in patients with MEN 1-associated tumors (146,151,152), but since the MEN 1 
syndrome could not be confirmed, the connection has been unclear. Recent studies have 
shown that mutations in the gene can be associated with PPGL (116,150) and a PCC has been 
found in a known MEN 1 patient (147), however due to small sample sizes and the 
difficulties of dividing the MEN syndromes, it is still unknown whether a causative 
association exists. In Paper II, among 68 non-familial tumors, we found one recurrent MEN1 
variant (p.Arg171Gln) in two PCCs and one PGL with unknown pathogenic significance 
(31). 
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MDH2 
In 2015, a 55 years old man with multiple malignant PGLs harboring a germ-line mutation in 
the malate dehydrogenase 2 (MDH2) gene was described (153). The MDH2 gene encodes the 
mitochondrial malate dehydrogenase enzyme that is also involved in the Krebs cycle. The 
patient was endowed with a heterozygous variant (c.429+1G>T) that affects a splice site in 
exon 4 and the authors conclude that MDH2 is a novel PPGL susceptibility gene (153).  
NF1 
The tumor suppressor neurofibromin, encoded by the neurofibromin 1 ( NF1) gene, is highly 
expressed in the nervous system and mutations have been found to cause the autosomal 
dominant NF1 syndrome (also called von Recklinghausen’s disease) (154). The gene is 58 
exons long (Figure 7), located at 17q11 and is known to promote conversion of RAS to its 
inactive form and thereby regulating cell proliferation through the ERK/MAPK signaling 
pathway (155) as well as serving as a regulator of TSC2 and mTOR (156) (Figure 10). 
Somatic NF1 mutations have been shown to be a frequent event in sporadic PCCs 
(31,117,118), and the mutations found in our cohort are shown in Figure 7 (31). Due to its 
length, normal Sanger sequencing is an expensive and time-consuming method to screen for 
NF1 mutations. Therefore, in Paper II we evaluated NGS as a tool for efficient mutation 
screening of all PPGL susceptibility genes, including NF1 (31). Patients harboring a germ-
line NF1 mutation and the NF1 syndrome often present symptoms of > 6 café au lait patches, 
axillary freckling, inguinal freckling, lichen eye nodules, optic gliomas, cutaneous 
neurofibromas (157) and 0.1- 5.7% of the patients develop unilateral PCC (158). In Paper III, 
we evaluated IHC as a screening tool for NF1 mutations but found a poor specificity for the 
method (159). 
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Figure 7.  
The NF1 gene. 
Schematic overview of the NF1 gene and mutational data among 86 PCCs from Paper II. The 
down-pointing arrow indicates the antibody (ab128054) binding position used in Paper III. 
Results from Immunohistochemical analysis are shown with ++ (strong/moderate 
immunoreactivity), + (uniformly weak immunoreactivity, +/- (focal areas with 
immunoreactivity or 0 (negative immunoreactivity) for each case. The picture is a modified 
version of a figure in Paper III.  
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RET 
GOF-mutations in the rearranged during transfection (RET) proto-oncogene are known to 
cause the MEN 2 syndrome (111,160), which is an autosomal dominantly inherited disease 
characterized by the development of endocrine hyperplasias and neoplasms including PCC 
(with a penetrance of 50% (161,162)), parathyroid adenoma and medullary thyroid carcinoma 
(MTC) (163,164). The gene is located at 10q11 and encodes a transmembrane receptor 
tyrosine kinase, a receptor that can activate the downstream RAS/RAF/MAPK and 
PI3K/AKT pathway cascades (165) (Figure 10). PCCs in MEN 2 patients are usually benign, 
secrete both NA and A and are often bilateral (68,166,167). Due to the occurrence of bilateral 
PCC, MTC and parathyroid adenomas, adrenal screening and prophylactic thyroidectomy 
may be considered. In Paper II, we reported both constitutional and somatic RET mutations. 
In addition to activating GOF-mutations that lead to MEN 2, inactivating mutations in the 
RET gene predispose to Hirschsprung’s disease, a disorder of the large intestine (168). 
SDHx 
Succinate dehydrogenase (SDH) is an enzyme complex that is connected to the inner 
membrane of the mitochondria and contains the four subunits SDHA, SDHB, SDHC and 
SDHD (64). SDHAF1 and SDHAF2 are also known to contribute to a functional SDH 
complex by regulating the SDHA subunit (169). The complex is involved in the tricarboxylic 
acid cycle (TCA) and in the respiratory electron transfer chain (ETC) with the roles of 
catalyzing the reaction from succinate to fumarate in TCA and transfer electrons to the 
succinate-CoQ reductase (Complex II) in the ETC (170). The proteins in the SDH complex 
are encoded by their respective succinate dehydrogenase (SDHx) genes; SDHA, SDHB, 
SDHC, SDHD, SDHAF1 and SDHAF2/SDH5. PPGL as tumor models became paradigm 
shifters when an inherited mutation of a gene encoding a metabolic enzyme (SDHD) was 
reported for the first time (64,110). The syndrome caused by constitutional mutations in the 
SDHD gene is therefore called PGL1 (Table 1). The SDHD discovery was subsequently 
followed by the findings of germ-line mutations in SDHC (171) and SDHB (172) causing the 
PGL3 and PGL4 syndromes, respectively. Eight years later, the PGL2 syndrome was found 
to be caused by germ-line mutations in the SDHAF2/SDH5 gene (173). A germ-line mutation 
in the SDHA gene is sometimes said to cause PGL5 that also include gastrointestinal stromal 
tumors (GIST), however this syndrome seem to have a lower PPGL penetrance compared to 
PGL 1-4 (174,175). Interestingly, from a clinical practice point of view, inactivation by 
mutations of the SDHB, SDHC and SDHD genes lead to decreased expression of SDHB that 
has been shown to be detectable by immunohistochemistry (IHC) (176,177). This has also 
been shown for SDHA IHC for SDHA mutated cases (178) and both SDHA- and SDHB IHC 
were recently verified as a reliable tools for mutation screening by the ENS@T network 
(179). In Paper V, we were able to verify the finding of SDHB IHC as a valuable tool for 
SDHA/SDHB mutation screening by testing 14 PCCs and 13 PGLs with known SDHx gene 
status (32). Moreover, since patients endowed with a germ-line SDHB mutation harbor a 
significantly higher risk of developing malignant disease (180) it is important to have a valid 
screening method to find these patients with a worse prognosis. This screening could be done 
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via SDHB IHC and/or sequencing of the SDHx genes, and maybe in the future via epigenetic 
screening for a hypermethylator phenotype (50,52,126). 
TMEM127 
Germ-line mutations in the Transmembrane protein 127 (TMEM127) gene were reported in 
PCC patients in 2010 (181) and subsequently verified as a novel PCC susceptibility gene with 
a prevalence of 1-2% (182,183). Mutations were found in patients with clinical criteria for 
inherited disease (bilateral PCC, young age at diagnosis or family history) (183). The gene is 
mapped to 2q11 and encodes a transmembrane protein (number 127) with TSG properties 
(181). PGLs seldom harbor TMEM127 mutations (184), and the penetrance of PCC among 
47 TMEM127 mutation carriers in one study was 32% (185).  
VHL 
The von Hippel-Lindau tumor suppressor (VHL) gene is mapped to 3q25, contains 3 exons 
(Figure 12) and inactivating germ-line mutations cause the vHL syndrome which is 
characterized by numerous tumor forms including PPGL, renal carcinomas, lymphatic sac 
tumors, hemangioblastomas and endocrine pancreatic tumors (68,186). The PPGL penetrance 
is 10-30%, about half of the PCCs are bilateral and malignancy seldom occurs (186,187). As 
further discussed under “Hypoxic response in PPGL” in this work, VHL is involved in the 
oxygen-sensing pathway through regulation of hypoxia-inducible factors (HIFs) that are 
known to increase expression of factors related to angiogenesis (188,189). Moreover, since 
HIFs are parts of the E3 ubiquitin ligase complex, the vHL protein is thought to be able to 
regulate the specific ligase activity resulting in ubiquitination and degradation of specific 
proteins (190).   
Genes associated with sporadic PPGL 
As described above, several of the genes for which germ-line mutations have been associated 
with a PPGL predisposition may also be somatically mutated in non-familial PPGL including 
EPAS1, MAX, NF1, RET and VHL (Table 1). In addition, a set of other genes exhibit somatic 
mutations in PPGL in varying frequencies including ATRX, FGFR1, HRAS, IDH1, KMT2D, 
MET and TERT.  
ATRX 
A recent study has shown that 12.6% of the PPGL investigated had somatic truncating and 
missense mutations in the alpha thalassemia/mental retardation syndrome X-linked (ATRX) 
gene (191). Germ-line mutations are known to cause the X-linked alpha thalassemia mental 
retardation syndrome and somatic mutations are known as drivers in neuroblastomas and 
gliomas (192–194). No germ-line mutation has been found in any PPGL patient and future 
work will further establish the ATRX mutation prevalence and the role in PPGL malignancy 
(191). 
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FGFR1 
Somatic mutations in the fibroblast growth factor receptor 1 (FGFR1) gene were recently 
identified via whole-exome sequencing (WES) of 16 matched PPGL and normal pairs (195). 
In a subsequent analysis of 80 sporadic tumors, mutations were found in three cases (3.8%) 
with one recurrent mutation (c.1638C>A) observed in two cases. Additionally, the tumors 
with mutations in the FGFR1 gene were found to cluster with NF1- and RET-mutated PPGL 
using mRNA expression profiling. (195) 
HRAS 
A somatic mutation in the Harvey rat sarcoma viral oncogene homolog (HRAS) gene was 
first described in a PCC in 1992 (196). Before that, 10 PCC had been screened for HRAS 
mutations but no mutations were found (197). Later, somatic mutations in the HRAS gene 
have been verified in four subsequent follow-up studies and revealed additional HRAS 
mutations as shown in Table 2 (Paper IV and (120,198,199)). Four different mutations have 
been found in the HRAS gene that are thought to promote PPGL tumorigenesis including 
G13R in exon 2 and Q61K, Q61R and Q61L (Figure 14) in exon 3. Constitutional mutations 
in the gene have been coupled to the Costello syndrome (200), however no co-existence of 
this syndrome and PPGL has so far been reported (120,198). 
IDH1 
A single somatic mutation (p.Arg132Cys) in the isocitrate dehydrogenase 1 (IDH1/NADP+) 
gene was found in a sporadic PGL in 2010 based on screening of 365 PPGL (201). The same 
codon 132 mutation has been described in more than 70% of grade II and III astrocytomas, 
oligodendrogliomas and glioblastomas (202), as well as in a few cases of prostate carcinomas 
and B-acute lymphoblastic leukemias (203).  
KMT2D/MLL2 
In Paper V, we describe missense variants of the gene lysine (K)-specific methyltransferase 
2D (KMT2D, also called ALR, MLL4, and MLL2) in 14 out of 99 PCCs (32). In a follow-up 
study (Paper VI), we showed absence of these mutations in 13 PGLs (204). The gene encodes 
KMT2D – a methyltransferase that can regulate the accessibility of DNA through histone 
methylation (205) and it has been previously shown that histone methylation is a central 
mechanism of epigenetic regulation at the genome-wide level (206). The Kabuki syndrome is 
a developmental disorder characterized by intellectual disability, distinctive facial marks and 
postnatal dwarfism which is caused by mutations in the KMT2D gene (207,208). So far, no 
PPGL patient has been reported with the Kabuki syndrome and vice versa. In Paper V, we 
found 14 missense mutations that were spread along the 54 exon-spanning gene, and five 
PCCs (36%) had somatic mutations in the functional FYR or SET domains (32) (Figure 8). In 
non-Hodgkin lymphomas, KMT2D has been shown to be recurrently mutated (209) as well as 
in medulloblastoma (210), urinary bladder carcinoma (211), esophageal squamous cell 
carcinoma (212) and lung cancer (213). It has also been shown that knockdown of KMT2D in 
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vitro affects cell growth and survival (214), which are in line with our results that KMT2D-
transfected PC12 cells exhibited a transcriptional profile enriched for genes involved in the 
regulation of actin cytoskeleton and focal adhesion (32).  
 
 
 
 
 
  
Figure 8.  
The KMT2D gene. 
Schematic overview of the KMT2D gene and mutational data among 99 PCCs from Paper 
V. Exon positions are indicated for each of the 14 KMT2D missense mutations together 
with the nuclear immunostaining of KMT2D where (+) denotes positive nuclear 
immunostaining, (+/-) denotes partially positive nuclear staining and (nd) means no data 
available. Green, gray and blue shaded areas indicate the functionally important FYR and 
SET regions of the gene. The picture is a modified version of a figure published in Paper 
V (32).  
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MET 
Five PCCs (2.5%) were found with hotspot mutations in the MET Proto-Oncogene (MET ) in 
a preceding study (215). The gene encodes for a receptor with tyrosine kinase activity that is 
able to activate the RAS/MAPK signaling pathway (Figure 10). The authors suggested a role 
of the MET mutations as a potential driver. However future studies might elucidate its 
involvement in PPGL tumorigenesis. 
TERT 
In a study from 2014 (listed among the related publications in this thesis - (216)) a mutation 
in the telomerase reverse transcriptase (TERT) gene was reported in one single benign PCC 
operated in CT, USA and in one metastatic PGL operated in Stockholm, Sweden. The TERT 
mRNA expression was also evaluated and found up-regulated in cases with mutations which 
could indicate telomerase activation. However, TERT expression was also found in wild-type 
cases, which could denote additional mechanisms of TERT activation, including epigenetic 
mechanisms. After this publication, two additional C228T mutations have been found in two 
PGLs (217). Mutations in the TERT promoter was first described in melanomas (218,219) 
and have subsequently been described in several human cancers (220). The TERT gene 
encodes the telomerase reverse transcriptase component of telomerase, which is known to 
elongate telomeres and commonly activated in many cancers (221). Another mechanism that 
can maintain telomeres not involving telomerase is called alternative lengthening of 
telomeres (ALT) and is dependent on homologous recombination (220). Interestingly, it has 
been shown that many ALT positive cancers harbor mutations in the ATRX gene (a recently 
found PPGL susceptibility gene as previously described) which encodes a protein that 
interact at telomeres. (222,223)  
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Table 1. Summary of all genes involved in PPGL tumorigenesis up to date, their prevalence 
and penetrance as well as the original reference work. Data regarding prevalence and 
penetrance is gathered from studies cited under respective gene name as above, which for 12 
of the genes are summarized in (64). 
 
Gene Syndrome 
Discovered 
in PPGL 
(year) 
Germ-line 
prevalence 
Somatic 
prevalence 
Penetrance 
of PPGL 
Original 
reference 
ATRX - 2015 0% 12.7% ND (191) 
BAP1 - 2012 1 case 0% ND (119) 
BRAF - 2015 0% 1 case ND (120) 
EGLN1 - 2008 <1% 0% ND (122) 
EPAS1 * 2012 <1% 7% ND (130) 
FGFR1 - 2015 0% 3.8% ND (195) 
FH - 2013 1% 0% <1% (126) 
HRAS - 1992 0% 5.8% ND (196) 
IDH1 - 2010 0% 1 case ND (201) 
KIF1Bβ - 2008 <1% 0% ND (138) 
KMT2D - 2015 <1% 14% ND (32) 
MAX - 2011 1-2% 1% ND (141) 
MDH2 - 2015 <1% 0% ND (153) 
MEN1 MEN1 2001 <1% 0% <1% (146) 
MET - 2015 0% 5 cases ND (215) 
NF1 NF1 1990 3% 15 - 25% 1-6% (112) 
RET MEN2 1993 5.3% 5% 50% (111) 
SDHA PGL5 2010 1% 0% ND (174) 
SDHAF2 PGL2 2009 <1% 0% 100/0%** (173) 
SDHB PGL4 2001 8% 0% 77% (172) 
SDHC PGL3 2000 <1% 0% ND (171) 
SDHD PGL1 2000 7.1% 0% 86/0%** (110) 
TERT - 2014 0% 4 cases ND (216) 
TMEM127 - 2010 1-2% 0% 32% (181) 
VHL vHL  1993  13%   9% 10-30%  (113) 
* A syndrome of paraganglioma and polycythemia has been suggested due to the finding of multiple 
PGLs and somatostatinomas associated with polycythemia as a result of GOF EPAS1 mutations (136). 
** PGL1 and PGL2 are commonly paternally inherited, proposing a maternally imprinting mechanism 
of the SDHD and SDHAF2 genes (224,225). Probably due to this imprinting, the penetrance is 
100%/86% for paternally inherited mutations and 0% for maternally inherited mutations. 
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Table 2. Summary of HRAS mutation studies in PPGL. The table is published in full in Paper 
IV. 
 
 
 
Gene expression and epigenetics 
Expressional profiling 
Preceding expressional profiling studies of PPGL have shown that the tumors can be divided 
into two distinct clusters that are strongly correlated with known drivers; Cluster 1 with 
tumors characterized by hypoxic response (EPAS1-, SDHx- and VHL-mutated tumors) and 
Cluster 2 with tumors characterized by active kinase signaling (HRAS-, MAX-, NF1-, RET- 
and TMEM127-mutated tumors) (137,226–229) (Figure 9). Also when studying the role of 
microRNAs
20
 (miRNA) in 69 PPGL, the miRNA signatures were shown to be specific to the 
genetic groups of PPGL (231). 
 
 
 
 
 
 
                                                 
20
 miRNAs are short and non-coding RNAs that have been shown to regulate gene expression in many 
biological processes. In cancer they regulate for instance proliferation, cell death and differentiation 
(230). 
  HRAS gene status   
PPGL susceptibility 
gene 
  
HRAS 
mutated 
codon 
13 
G13R 
codon 
61 
Q61R 
codon 
61 
Q61K 
codon 
61 
Q61L 
Wild-
type 
codon 
13/61 
 
Known 
mutation 
Unknown 
mutation 
(sporadic) 
HRAS mutations in eight studies  
       
  - PCC (n = 814) 
46 
(5.7%) 
5 
(0.8%) 
26 
(4.0%) 
5 
(0.8%) 
0 
768 
(94.3%)  
1 / 330 
(0.3%) 
45 / 484  
(9.3%) 
  - PGL (n = 136) 
3   
(2.2%) 
0 
1  
(0.9%) 
1 
(0.9%) 
1 
(0.9%) 
133 
(97.8%)  
0 / 72 
3 / 64  
(4.7%) 
  Total (n = 950) 
49 
(5.2%) 
5 
(0.7%) 
27 
(3.6%) 
6 
(0.8%) 
1 
(0.1%) 
901 
(94.8%) 
  
1 / 402 
(0.2%) 
48 / 548 
(8.8%)  
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Figure 9.  
Clustering of PPGL. 
Hierarchical clustering in a dendrogram of 
PPGL based on their expression levels for 
454 genes according to Burnichon et al. 
2011 (227).  
The image shows clear separation of PPGL 
into two groups based on their genetic 
background. This is a modified version of a 
figure included in Paper IV. 
 
 
 
 
 
 
 
 
  
Cluster 1 
Cluster 2 
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Hypoxic response in PPGL, Cluster 1 
Pseudo-hypoxia driven tumors in Cluster 1 have the characteristics of activating hypoxia 
inducible factors (HIFs). Under conditions of low cellular oxygen levels, HIFs (HIF-1 and 
HIF-2) can activate genes that promote a range of functions including survival, pH regulation, 
cell migration and tumor growth (232,233). When the HIFs (1 and 2) are active they consist 
of two subunits; α and β. The HIF-1β subunit is quite stably expressed and can dimerize with 
(and activate) both HIF-1α and HIF-2α (the latter encoded by EPAS1 and discussed under 
PPGL etiology) (232,234). The fact that the β unit is constitutively expressed makes the α 
units the main regulators of the HIFs and are in turn controlled by hydroxylation by prolyl 
hydroxylases (PHDs) (235). Two PHDs, encoded by PHD1 and PHD2 are further described 
under hereditary predisposition for PPGL since EGLN1/PHD2 has been found with a 
mutation in a patient with polycythemia and PGL (122). Once a prolyl residue of a HIF is 
hydroxylated by a PHD, it can be ubiquitinated and degraded via the von-Hippel Lindau 
protein (vHL, as also discussed under PPGL etiology) containing an E3 ubiquitin ligase 
complex (236). The condition pseudo-hypoxia occurs when a HIF-α unit cannot be degraded 
due to inactivation of any molecule in the chain described, regardless of cellular oxygen 
levels (190). Additionally, it is currently hypothesized that inactivation of subunits of SDH 
lead to succinate accumulation which inhibits alpha-ketoglutarate (126), which in turn 
inhibits EGLN/PHD (237). When PHD is inactivated it cannot hydroxylate HIF-α (as 
discussed above) resulting in activation of HIF (124) that may lead to several changes in the 
cell including tumor growth and migration. It has been shown that inactivation of FH lead to 
the same end result of activated HIF (124,238) and possibly the other metabolic enzymes 
IDH1 and MDH2 could theoretically have a similar function in PPGL. 
Activation of kinase signaling pathways, Cluster 2 
Tumors in Cluster 2 are associated with activation of the kinase signaling pathways 
RAS/RAF/MAPK and PI3K/AKT, both well known to be aberrant in various cancers causing 
both cell proliferation and cell survival (239,240). In PPGL, mutations in both NF1 and RET 
causing NF1 and MEN2 syndromes respectively, can activate both pathways although NF1 is 
known as a TSG and RET as an oncogene (156,226,241,242). An activation of the RET gene 
through a GOF mutation can inhibit RAS (which is partly encoded by HRAS [in addition to 
KRAS and NRAS] and discussed under PPGL etiology) and also activate PI3K signaling as 
visualized in Figure 10. Likewise, an inactivation of the NF1 gene can inhibit RAS which in 
turn can activate PI3K (64,68). TMEM127, another mutated gene in cluster 2 is hypothesized 
to inhibit mTOR activity (181) and the MAX gene is thought to inhibit MYC (142) which in 
turn can activate HIF (cluster 1) and cause cell proliferation itself through 4EBP1 (as shown 
in lymphomas (243)) like mTOR (Figure 10) (64,68). The cross-talk and clustering overlap 
mentioned for MAX is interesting since MAX-associated tumors align in cluster 2 and hence 
do not show a pseudo-hypoxic gene profile, but could possibly affect HIF (Figure 10) and do 
also show a low expression of PNMT and low levels of norepinephrine secretion (64,142).   
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Figure 10.  
PPGL susceptibility genes and their interactions in cluster 2. 
The membrane bound protein RET and other membrane bound growth factor tyrosine 
receptors (GFR) are when activated able to initiate a cascade of downstream events that 
lead to activation of the RAS/RAF/MAPK and PI3K/AKT pathways including mTOR. 
Proteins encoded by genes that have been found with activating mutations (GOF) in 
PPGL are shown in red boxes and those with inactivating mutations (TSG) are shown in 
blue boxes. Activating pathways are shown with arrows and inhibiting ditto are shown 
with dashed lines.  
Once mTOR is activated it can regulate cell growth through lipid-, DNA and protein 
synthesis (the latter through inhibition of 4EBP1 that inhibits protein translation) as well 
as glucose uptake through HIF. Other regulators are NF1 that inhibits RAS and 
TMEM127 that is thought to inhibit mTOR. The underlying mechanisms of MAX in the 
PPGL tumorigenesis is not yet clearly shown although the MAX-MYC dimers promote 
and MAX-MXD1 dimers inhibits cell proliferation. MYC in turn has also been shown to 
inhibit 4EBP1 and cooperates with mTOR to both increase protein translation and glucose 
uptake (via HIF). Cross-talk between MAPK and MYC has also been suggested. The 
picture is inspired from figure 3 in (64) and figure 3 in (68). 
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Epigenetics 
Epigenetic aberrancies including DNA methylation have been shown to contribute to PPGL 
tumor development. In Paper V we report mutations in a gene encoding a methyltransferase 
that can regulate the accessibility of DNA through histone modification (32). In 2005, 
Dammann et al. showed promoter hypermethylation in subsets of PCCs for RASSF1A, p16, 
MSH2, CDH1 and PTEN (244). This was followed by the findings by Geli et al. who showed 
hypermethylation of NORE1 as well as coupled hypermethylation of RASSF1A to malignant 
behavior of the tumor (245). In 2008, Geli et al. defined a CpG island methylator phenotype 
(CIMP) for PPGL that exhibited hypermethylation in three or more genes in the following list 
of 11 genes: p16
INK4A
, CDH1, DCR2, RARB, RASSF1A, NORE1A, TP73, APC, DAPK1, 
p14
ARF
 and PTEN (246) which was first described in colon cancer (121). The patients with 
CIMP were mostly young patients with paraganglioma and/or malignant disease. It was 
found that SDHB mutations are associated with a CIMP phenotype (52,246) which later also 
was established in a mouse model (126). It was hypothesized that SDHB mutation predispose 
to CIMP and that CIMP occur before the tumor exhibit malignant features (52). It is thought 
that mutations in the SDHx/FH genes affect the Krebs cycle to succinate accumulation which 
leads to inhibition of DNA/histone demethylases. This inhibition leads consequently to 
hypermethylation which can inactivate key genes that are related to PPGL tumorigenesis and 
malignancy (52,126). In this way, epigenetic mechanisms contribute to the regulation of 
metabolic gene expression which sometimes is referred to as the “Warburg effect” (25), from 
the Nobel laureate Otto Warburg. To expand on this, the effect describes how cancer cells 
regulate their aerobic respiration and preferentially use glycolysis to generate energy, which 
has been shown for PPGL (247). 
In Paper I, we proposed inactivation of the PPGL susceptibility gene VHL through promoter 
methylation in PPGL (51). In 2013, Letouzé et al. performed a genome-wide screening for 
altered DNA methylation with the Illumina based methylation profiling of 27k CpG sites 
among 145 tumors and related the findings to the gene expression clusters as described above 
(126). The authors were able to identify three main clusters of hypermethylation that 
corresponded to gene mutation, gene expression and also poorer survival for patients in the 
M1 cluster (characterized by hypermethylation at a large number of CpG sites) (126).  
Treatment of SDHB- related, malignant PPGL with temozolomide (TMZ) has been shown to 
be an effective antitumor agent, and it is hypothesized that the finding is explained by 
silencing of MGMT expression as a consequence of MGMT promoter hypermethylation in 
SDHB-mutated PPGL (248). 
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AIMS 
A total of six studies are included in the thesis, with the overall aim to further characterize 
molecular and genetic alterations of importance in the development of PPGL. The overall 
aims, specific for each paper were: 
PAPER I  
- To evaluate the promoter methylation status of the PPGL susceptibility genes. 
PAPER II  
- To develop a next-generation sequencing method for mutational screening of the 
known PPGL susceptibility genes.   
PAPER III 
- To examine whether mutations in the NF1 gene could be predicted by 
immunohistochemistry.  
PAPER IV 
- To establish the HRAS mutation frequency and investigate the expressional profiling 
of HRAS mutated PPGL.  
PAPER V 
- To search for novel genes involved in the PCC tumor development by whole exome 
sequencing.  
PAPER VI 
- To determine the prevalence of KMT2D mutations in PGL. 
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MATERIAL AND METHODS 
“Experiment is the only means of knowledge at our disposal. Everything else is poetry, 
imagination.” – Max Planck.  
MATERIAL / STUDY POPULATION 
This thesis comprises tumor and corresponding normal tissue samples mainly obtained from 
the endocrine biobank at Karolinska University Hospital, Sweden. In Paper IV, tumors were 
also collected from University de Lorraine, Vandoeuvre-les-Nancy, France, Linköping 
University Hospital, Sweden and Haukeland University Hospital in Bergen, Norway. In 
Paper V, a subset of tumors was obtained from Yale University in New Haven (CT), USA. 
Additionally, a PC12 rat pheochromocytoma cell line was used in Paper V. 
In 1986 at the Karolinska University Hospital, the endocrine biobank project was initiated, in 
which surgically removed endocrine tumors and other tissues samples are stored at -80 °C 
after immediate freezing in liquid nitrogen (249). After operation, an experienced pathologist 
identified and dissected the tumor and normal tissue which were subsequently used for 
extraction of the specific analytes DNA, RNA and protein. Additionally, a small 
representational piece was cut from almost all samples (Figure 11) and was fixed in 
formaldehyde, embedded in paraffin, sectioned and stained with haematoxylin and eosin 
(H&E). Subsequently the tumor and normal cell content was determined, often by two expert 
pathologists independently.  
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 11.  
Tissue sampling for extractions and representativity testing. 
Schematic overview of the tissue sampling method prior to extraction of analytes (RNA, 
DNA and Protein) and representativity testing (H&E). 
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For the cases from the Karolinska biobank, genomic DNA from tumor and normal tissues 
was extracted with the DNeasy DNA isolation kit (QIAGEN) and validated using the Nano-
Drop technology. Genomic DNA extraction from blood (used in Paper II and V) was 
performed with the QIAamp DNA Blood Midi Kit (QIAGEN). RNA extraction was 
performed using the mirVana miRNA Isolation Kit (Ambion/Invitrogen) and the RNA 
quality was assessed using an Agilent 2100 Bioanalyzer (Agilent) obtaining RIN values that 
have been shown to be sufficient after long-term storage (249). Protein extracted from the 
tumors is often used for Western Blot (250) but has not been used in any of the papers 
included in this thesis, although protein extracted from PC12 cells has been used for KMT2D 
protein validation in Paper V. DNA from the other universities was extracted using 
standardized methods similar to the procedure used at Karolinska; involving lysis of tissue, 
precipitation in ethanol, binding of the analyte to a spin column membrane and elution of the 
analyte with water after multiple washing. For IHC, tissue samples were fixed in 4% 
formaldehyde, embedded in paraffin and later sectioned and stained with the specific primary 
antibodies as specified in the papers and below. 
METHODS 
Genetic analysis 
Sanger sequencing and Polymerase chain reaction (PCR) 
Since the initial report in 1977, Sanger sequencing has become the golden standard method 
for DNA sequencing (251). The method involves the use of fluorescent dyes for each 
nucleotide that emit light at different wave-lengths. After amplification of the specific target 
with a polymerase chain reaction (PCR), the nucleotides are detected by the fluorescent 
emission after dye-termination sequencing. In this thesis, sequencing was carried out at the 
KiGene core facility at Karolinska Institutet for most of the cases. The method was used in 
Papers I, IV and V and the specific primers were mostly designed with the NCBI Primer 
Blast (http://blast.ncbi.nlm.nih.gov). The sequencing results were analyzed by visual 
examination of the chromatograms obtained from the dye-termination sequencing (Figure 
14), using both Chromas (Technelysium) and CodonCode Aligner software.  
Reverse transcription and quantitative real-time PCR 
Quantitative real-time PCR (qRT-PCR) is a method used in Papers I, V and VI to 
quantitatively measure the amount of cDNA and specific genes during the progress of a PCR 
in real-time. Primarily, mRNA extracted from tumor and normal tissue was converted to 
cDNA via reverse transcription and the High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems). The TaqMan assays were pre-designed from the manufacturer 
(Applied Biosystems) and constitute of two primers and one probe that anneal to the cDNA 
template. In the PCR reaction, the number of the PCR cycle in which the product amount 
exponentially increases is used to calculate the starting amount of the specific template (252) 
which often is referred to as the gene expression. The expression of a specific gene is often 
related to one or several endogenous controls that are specific to the analyzed tissue. In Paper 
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I, as an effort to completely follow the Minimum Information for Publication of Quantitative 
Real-Time PCR Experiments (MIQE) guidelines (252), 32 different endogenous control 
genes were tested in triplicates for 6 different PPGL and normal adrenal tissue samples. It 
was found that the most stable endogenous controls with the smallest variation among the 
samples were the B2M, CASC3, MRPL19, PSMC4, and UBC genes which subsequently were 
used as endogenous control genes for PPGL in the following papers (51). 
Copy Number Analysis  
In Paper V, genomic DNA from the tumors were analyzed for KMT2D gene copy number 
alterations using a commercially available KMT2D TaqMan copy number assay on a 
StepOnePlus system (Invitrogen/Life Technologies). The experimental procedure is 
essentially as briefly described above under qRT-PCR. The number of PCR cycles at which 
the DNA amount increases and reaches a specific threshold was used to calculate the number 
of KMT2D gene copies for each sample.   
Bisulfite Pyrosequencing 
Pyrosequencing was originally developed in 1996
21
 for analysis of SNPs (253) but has since 
become a gold standard method for quantitative detection of DNA methylation. The method 
was used in Paper I in this thesis. When Pyrosequencing is used for assessment of DNA 
methylation, the methylated DNA needs to be separated from unmethylated DNA using 
sodium bisulfite treatment. During this treatment, methylated cytosine residues are unaffected 
while unmethylated cytosine residues are converted to uracil (U, complementary to T). The 
differences between C and T (methylated/unmethylated cytosine residues) can be 
quantitatified by Pyrosequencing which always is preceded by a PCR of the bisulfite treated 
DNA and amplification of the specific template and the CpGs of interest. Commercially 
available primers (PyroMark Assay Database, Geneglobe, Qiagen) and in-house designed 
primers (PyroMark Assay Design software, Qiagen) were used, both resulting in a 
biotinylated reverse primer that binds the PCR fragments on streptavidin-coated sepharose 
beads. After vacuum removal of the forward strand, a sequencing primer (often closely 
related to the forward primer strand) is added to the immobilized reverse strand on the 
sepharose beads and the Pyrosequencing reaction can be started. During this reaction, the 
nucleotides are dispensed one by one to the (reversed) template while a pyrophosphate group 
is simultaneously cleaved off if the nucleotide is incorporated, resulting in a flash of light that 
is measured and registered. The intensity of this light is proportional to the amount of 
nucleotides that could be incorporated and used to calculate the sequence. Since both C and T 
are dispensed to the specific methylated/unmethylated CpG sites, the C/T light intensity ratio 
is used to calculate the level of methylation at this site.  
                                                 
21
 The technique was invented at the Royal Institute of Technology (KTH) in Stockholm by Mostafa 
Ronaghi, Mathias Uhlén and Pål Nyrén (253). 
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Next generation sequencing (NGS) 
The challenge to deliver fast, accurate and inexpensive genome information has driven the 
development of next-generation sequencing (NGS) technologies that allow massive parallel 
sequencing and production of genetic data at a low price compared to the previously 
described Sanger sequencing method (254). In this thesis, both targeted sequencing and 
whole-exome sequencing (WES) have been used – collectively known as NGS. 
Targeted sequencing 
In this thesis, a targeted sequencing approach was undertaken to analyze the known PPGL 
susceptibility genes (Paper II), and all exons of KMT2D (Papers V and VI) respectively. 
Probes were designed to allow simultaneous sequencing of all targets (all exons of the 
following genes: EGLN1, EPAS1, KIF1Bβ, MAX, MEN1, NF1, RET, SDHA, SDHB, SDHC, 
SDHD, SDHAF2, TMEM127 and VHL in Paper II, and KMT2D in Paper V and VI). The 
targets were labelled and barcoded to tolerate massive pooling of multiple samples. The 
samples and the pool of amplicons were analyzed on an Illumina MiSeq instrument (Paper II) 
or an Illumina HiSeq instrument (Papers V and VI), and the obtained sequences were 
subsequently aligned to the reference genome. In short, the targets are bound to primary 
adapters that in turn are able to bind to other, secondary adapters that are attached to the 
surface of an Illumina flow cell, like sprucely organized trees in a forest that only one single 
unique squirrel can attach (to use a metaphor). The secondary adapters are used as primers in 
an amplification reaction within the flow cell and a reaction referred to as sequencing by 
synthesis is initiated when labeled nucleotides are added to the flow cell, one by one. An 
image is captured of the flow cell after each added nucleotide where an emitted light from 
each adapter (tree) shows whether the nucleotide could be incorporated. The series of 
captured images can be read by the instrument to construct a sequence.  
Whole-exome sequencing 
As the exons (including the coding regions of the DNA) only constitute approximately 1% of 
the human genome, sequencing of those regions has been shown to be efficient for 
identification of novel functional mutations (255). Also, since PCR amplification of each 
coding sequence is expensive and cumbersome, this new method is today playing a major 
role in disease gene discovery and also in the clinical setting at some university hospitals. In 
Paper V and VI, we used the NimbleGen whole-exome protocol for labeling of DNA, 
followed by sequencing on an Illumina HiSeq platform (32,204) as described above and 
previously in a published article (255). Both tumor- and matched normal blood/tissue DNA 
were included in the WES approach. The sequences were subsequently aligned to the human 
reference genome using standardized protocols (ELAND, Illumina). Differences between 
reference and non-reference read proportions between tumors and their corresponding normal 
sample were called variants or indels, and the significance of the aberrations were statistically 
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calculated (Fisher’s exact test). Constitutional variants that were annotated in the 1000 
Genomes database
22
 were excluded.  
siRNA transfection, stable over-expression and cell motility 
In Paper V, functional studies regarding KMT2D were performed in which PC12 cells (rat 
pheochromocytoma) were used for both siRNA transfection (knock-down) and stable 
transfection (over-expression) of KMT2D in a mock medium (lipofectamine-2000, Life 
technologies). For the siRNA transfection, siRNA targeting KMT2D was used and for the 
constitutive transfection, Neo- and MLL2- plasmid vectors were used (Origene). The 
transfection efficiencies were verified using qRT-PCR for both KMT2D silencing and over-
expression. After siRNA transfection, the migratory potential of the cells were measured after 
4, 12, 16 and 24 hours using modified Boyden Chambers (BD Biosciences), and after the 
over-expression the cell motility was measured through counting of migrated cells after 2, 4, 
8 and 12 hours. Additionally, protein was extracted from the cells and used for Western Blot 
analysis of the KMT2D protein. RNA isolated from KMT2D over-expressing cells and mock-
transfected
23
 PC12 cells was used for gene expression profiling as described below. 
Gene expression microarray 
While qRT-PCR was used to analyze the expression of individual genes, an Affymetrix-
based RNA microarray approach was used in Paper IV and V for genome-wide analysis of 
~29k annotated genes (32). Microarray analysis uses the same basic principle with a flow cell 
as described for targeted sequencing above, but with the difference that oligonucleotides are 
arranged at a surface that are able to recognize and attach to cDNA. In Paper V, the overall 
gene expression profiles between KMT2D over-expressing and mock-transfected PC12 cells 
were studied. For both Papers IV and V, the same microarray platform was used, but with 
different Gene Chips to analyze the human and rat genome respectively. For the Affymetrix 
microarray, a median of 26 probe sets covered each gene from which a mean was calculated 
as a measurement for the specific gene expressions. Benjamini-Hochberg calculations were 
used to correct for multiple testing and t-tests were performed for testing of differentially 
expressed genes between the sample groups. In Paper IV, after normalization, hierarchical 
clustering of the microarray expression data was performed using a gene set of 454 genes as 
defined by Burnichon et al. (227) 
                                                 
22
 According to the 1000 Genomes homepage (www.1000genomes.org), the project is the first effort 
to sequence the genomes of a large number of people, with the goal to find the most genetic variants 
that have frequencies of at least 1% in the population to provide a complete resource on human 
genetic variations. 
 
23
 Mock-transfected cells are treated with the transfection reagent only and no addition of siRNA. 
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PCR product cloning 
In Paper II, two EPAS1 mutations were found in the same tumor. In order to investigate if the 
mutations occurred on the same or on different alleles, a technique to clone the PCR product 
into a vector was used (31). The technique involves transformation of the vector into E.coli 
bacteria cells and is thoroughly described in a related publication where the EPAS1 gene was 
analyzed in detail (137).  
Protein analysis 
Immunohistochemistry (IHC) 
The IHC method used to detect proteins in tissue sections, was invented in 1950 (256) and is 
still in use as a diagnostic tool in the clinical practice as well as in research. The method was 
used in this thesis to detect protein expression of NF1 (Paper III), and of KMT2D, H3K4me3, 
H3K27me3 and SDHB (Papers V and VI). By application of a primary antibody that is 
directed to a specified target amino acid sequence (epitope), the target protein can be 
identified and visualized in the tissue section. The method can provide information about 
presence and subcellular localization, or absence of the protein investigated. The avidin biotin 
complex (ABC) method that amplifies the signal intensity was used for protein detection in 
all papers included in this thesis where IHC has been performed. If the amplification obtained 
by the ABC kit is not preferred, a HRP-conjugated secondary antibody can be used instead.  
IHC is performed on 4 µm thin paraffin embedded slides, and prior to the antibody 
incubation, xylene is used to remove the paraffin in order to get access to the proteins in the 
tissue. Heated citrate solution was used for antigen retrieval for all cases, and since our 
developing method (with 3,3'-Diaminobenzidine, DAB chromogen) is based on a peroxidase 
reaction, endogenous peroxidases in the tissues need to be inhibited with a hydrogen peroxide 
(H2O2) solution. As the ABC method uses the proteins avidin and biotin to visualize the 
target, endogenous avidin and biotin is blocked with biotin and avidin respectively. The 
biotinylated secondary antibody has a high affinity to the primary antibody and the avidin 
used in the ABC solution binds to the biotin attached to the secondary antibody. In order to 
avoid unspecific binding of the secondary antibody, the slides need to be blocked with a 
protein solution (such as bovine serum albumin). When DAB and H2O2 is added, a brown 
color appears when H2O2 is converted to O2 and H2O by the peroxidase that is attached to the 
avidin (which is attached to the biotin of the secondary antibody).  
Primary antibody incubations were performed in wet chambers over night at different 
concentrations for the different antibodies used in Papers III, V and VI. After counterstaining 
in HTX, the slides were evaluated in a graded scale as presented in the papers (32,159,204).  
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RESULTS AND DISCUSSION 
 
I - EPIGENETIC INACTIVATION OF THE VHL GENE 
In Paper I (51), we sought to investigate the susceptibility gene promoter methylation status 
in a large cohort of PPGL. This was performed by bisulfite Pyrosequencing of the promoter 
regions of the following 11 genes: EGLN1, MAX, MEN1, NF1, RET, SDHAF2, SDHB, 
SDHC, SDHD, TMEM127 and VHL in 96 tumors and 34 normal adrenal samples. For all 
genes except VHL and RET, both PPGLs and normal adrenal tissue samples exhibited low 
levels of promoter methylation. Regarding the RET gene, promoter hypermethylation was 
observed in two single PGLs. The main finding of the study was a frequently observed 
increase of VHL promoter methylation levels. The VHL methylation levels were increased in 
PGL compared with PCC, in PPGL compared with normal adrenal samples and in malignant 
PPGL compared with benign tumors. To expand on this, we studied the VHL gene expression 
with qRT-PCR and found an inverse correlation between VHL methylation status and VHL 
mRNA expression. Previous efforts for assessing the methylation levels of the PPGL 
susceptibility genes have failed to find hypermethylation of the VHL promoter 
(53,118,126,244). The discrepancy is probably stemming from the fact that the CpG sites 
analyzed in those studies are not same as the ones assessed herein (Figure 12). Specifically, 
Welander et al. (118), Dammann et al. (244) and Cascón et al. (53) used primers as indicated 
in blue in Figure 12, originally designed by Herman et al. (257) while Letouzé et al. (126) 
used the Illumina HM27 (27K) methylation assay covering 27578 CpG sites with the closest 
dinucleotide located around 800 bases downstream of the sequence in this study. 
Interestingly, we found that the methylation density of the four individual CpG sites analyzed 
in our assay differed with higher levels of methylation at the early positions. Since the 
sequences of all other attempts of assessing the VHL promoter methylation levels are located 
downstream of our assay as indicated in Figure 12, it might be a true phenomenon that the 
methylation levels are decreasing downstream of the promoter region. 
In summary, our results indicate that the VHL gene is inactivated through promoter 
methylation and that the hypermethylation could play a role in the PPGL development. Since 
the publication of the study in 2013, it has been found that several Ras-association domain 
family members (RASSF) also are hypermethylated in their promoter regions and could play 
a role in the tumor development (258).  
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Figure 12.  
Overview of the start of the VHL gene and its promoter region. 
The VHL gene is located on chromosome 3, at 3p25.3 and transcript 1 consists of three 
exons as shown in blue and white. The bisulfite treated, methylated sequence of the gene 
differs from the human reference since unmethylated cytosine (C) residues are converted 
to thymidine (T). The sequences analyzed here and in other publications are indicated in 
different colors and by arrow. The figure is modified from Paper I, figure 4 (51). 
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II - IDENTIFICATION OF RARE GERM-LINE MUTATIONS 
In the second study (31), we identified rare germ-line mutations and characterized somatic 
mutations by targeted sequencing of the PPGL susceptibility genes in 86 PPGL. The targeted 
sequencing approach (Illumina MiSeq) was designed to cover all exons of the genes that (at 
the time of the study design) were known to be associated with PPGL: EGLN1, EPAS1, 
KIF1Bβ, MAX, MEN1, NF1, RET, SDHA, SDHB, SDHC, SDHD, SDHAF2, TMEM127 and 
VHL. All suspected mutations/variants found with the MiSeq sequencing were verified with 
Sanger sequencing in the tumors and also investigated in corresponding constitutional DNA 
when available. The sequencing approach was found to be significantly faster and 
economical compared with Sanger sequencing. A possible drawback of the technique is that 
since the publication of the study, the susceptibility gene list has grown rapidly and frequent 
updates of the gene coverage design is therefore needed. Additionally, there is always a risk 
of incidental findings of mutations/variants when screening many genes. This might lead to 
ethical issues both for the patient and physicians due to the difficulties of evaluating the 
pathogenicity of novel variants. 
As the title indicates, rare germ-line mutations were found including one KIF1Bβ mutation in 
the constitutional tissue of a patient with a PCC. Also, a somatic KIF1Bβ mutation was found 
in a PCC already known to be endowed with a NF1 gene mutation. Patients endowed with 
germ-line mutations were generally younger at their age of diagnosis compared to the patients 
with somatic mutations. Moreover, the most frequently mutated gene was NF1, followed by 
EPAS1 and RET. One PGL harbored two EPAS1 mutations that after PCR product cloning 
was found to occur on the same allele. No mutations were found in MEN1, SDHC, SDHD or 
SDHAF2. For the other genes, mutations were found in frequencies as previously published.  
In summary, we found that a large subset of the PPGL investigated was endowed with 
mutations in PPGL susceptibility genes. We also proved the usefulness of targeted 
susceptibility gene sequencing for genetic screening that might be considered in the clinical 
setting. 
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III - NF1 IHC DOES NOT PREDICT NF1 GENE MUTATIONS  
In Paper II, it was found that the NF1 gene is the most frequently mutated gene in PPGL 
patients, both in tumors and in the germ-line DNA of the patients. To follow up on this, In 
Paper III (159), we sought to investigate if the NF1 mutations reflect an aberrant NF1 protein 
expression and also whether NF1 IHC could be used as a screening tool to find patients for 
further (germ-line) genetic testing of the NF1 gene.  
We included a total of 67 PCCs (with known NF1 gene status: 49 NF1 wild-type and 18 NF1 
mutated) and assessed NF1 expression using IHC. Although the majority of the NF1 mutated 
PCCs displayed absent NF1 immunoreactivity, the NF1 expression was only retained in a 
minority of NF1 wild-type PCCs. Our data therefore indicate that NF1 IHC exhibits a robust 
sensitivity but poor specificity for use as a screening tool for NF1 mutations, and hence 
cannot be recommended as a clinical adjunct for screening purposes. Therefore, in the clinical 
context, family history of NF1 phenotypes, co-occurrence of other clinical NF1 
characteristics and genetic screening therefore remains the most efficient and reliable tool to 
pinpoint these patients. However, the finding of absent NF1 expression in the majority of 
NF1 wild-type PCCs suggests important alternative modes of NF1 inactivation apart from 
mutations.  
Interestingly, the NF1 immunoreactivity was specifically prominent in those tumor cells close 
to the tumor capsule and around blood vessels (Figure 13). Although this phenomenon stands 
without a credible explanation; we hypothesized that regional differences in NF1 degradation 
and/or subclonal expansions of NF1 could underlie the obtained staining patterns.  
In summary, we found that NF1 IHC alone is not a sufficient tool for NF1 mutation 
screening.  
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Figure 13.  
NF1 immunoreactivity around blood vessel. 
The image shows a previously unpublished NF1 staining of a PCC with strong, prominent 
NF1 immunoreactivity (brown) around a blood vessel (blue), a phenomenon without an 
obvious explanation. Cell nuclei are stained blue.  
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IV – ASSESSMENT OF HRAS MUTATION PREVALENCE AND ASSOCIATED 
EXPRESSION PROFILE 
In Paper IV, we characterized the HRAS mutation prevalence in a large cohort of tumors and 
investigated the expressional profiling of HRAS mutated tumors. Since the publication of 
Paper II, new PPGL susceptibility genes have been verified with HRAS as one of them. To 
further study the PPGL etiology we collected 156 PPGL (142 PCCs and 14 PGLs) and 
screened them for mutations in the HRAS gene. We found activating HRAS mutations in 
11/156 (7.1%) cases and identified a novel HRAS mutation (Q61L) in a PGL (Figure 14). 
Additionally, we compared the HRAS mutation status with microarray-based gene expression 
profiles for a previously defined set of 454 genes (227) for 93 of the cases.  
All tumors with HRAS mutations included in the mRNA expression profiling were found to 
cluster together with the NF1- and RET-mutated tumors (Figure 9). The gene expression 
profiles of these tumors have been shown to be associated with kinase pathway activation 
(Figure 10). We also found that somatic HRAS mutations did not occur in patients with any 
other known PPGL susceptibility gene driver event which is in line with preceding findings 
(120,198,199,215) and none of the HRAS-mutated tumors in our cohort were malignant.  
Taken together with the previously published frequencies of HRAS mutations in PPGL, the 
overall HRAS mutation frequency was calculated to 5.2% among all PPGL and 8.8% among 
PPGLs without known susceptibility gene mutation (Table 2). 
In summary, our data suggest a role of HRAS mutations as a somatic driver event in benign 
PPGL and that HRAS mutated pheochromocytomas cluster together with NF1- and RET-
mutated tumors associated with activation of kinase pathways.  
c.182A>T, Q61L 
Figure 14.  
Chromatogram of a PGL with the HRAS Q61L mutation. 
The figure shows the Q61L mutation in a PGL (c.182A>T, COSM498), in a reversed 
complementary sequence. The heterozygous variant is shown in the middle of the 
chromatogram.  
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V - IDENTIFICATION OF KMT2D AS A RECURRENTLY MUTATED GENE IN 
PCC 
 
In the fifth study (32), we characterized a discovery cohort of 15 PCCs devoid of mutations in 
established PCC susceptibility genes using WES of matched PCC and normal tissue samples 
with the aim of detecting novel driver genes. Besides KMT2D as the title indicates, several 
interesting variants were identified including mutations in known cancer genes such as ZAN, 
MITF, WDTC1, CAMTA1 and CDKN2C. A low rate of 6.1 non-silent single nucleotide 
variants (SNVs) per sample was detected. Among the 15 PCCs, one somatic HRAS mutation 
and one somatic EPAS1 mutation were observed as the only PPGL related genes.  
In the discovery cohort, two somatic mutations and one constitutional mutation were found in 
the KMT2D gene in one sample each. Further focused screening of 83 additional PCCs led to 
the detection of KMT2D mutations/variants in 11 additional cases, of which two were 
recurrent in two samples each (N5223S and G2735S) (Figure 8). Altogether, heterozygous 
missense KMT2D mutations were found in 14 (11 somatic, two constitutional, one 
undetermined) out of 99 PCCs, resulting in an overall KMT2D mutational frequency of 14%. 
Five of the 14 KMT2D mutations (36%) were found in the functional FYR or SET domains 
of the gene (Figure 8). Further expressional analysis using qRT-PCR showed that KMT2D 
expression was significantly up-regulated in PCCs as compared to normal adrenal tissue 
samples. Copy number analysis showed that the vast majority of PCCs (91%) carried two 
copies of KMT2D while 2% of the cases exhibited one copy, 6% three copies and 1 case (1%) 
had four copies of the gene. IHC showed a positive correlation between KMT2D mutations 
and KMT2D and H3K4me3 nuclear staining, a finding that might suggest that the mutations 
affect histone methyltransferase activity.  
As the size of the KMT2D gene substantially obstructed a site-directed mutagenesis approach 
to test the pathogenicity of the mutation(s), we instead chose to study the effects of KMT2D 
over-expression. This showed that KMT2D over-expression positively affected cell migration 
in a PCC cell line. Furthermore, the expressional profile of PC12 cells with and without 
KMT2D over-expression was determined using an Affymetrix microarray technique. A 
significant difference in expressional patterns between mock-transfected and transfected 
PC12 cells was found for a total of 594 transcripts and gene ontology analysis suggested an 
enrichment of genes within the TGF-beta signaling network and extracellular matrix-receptor 
interaction pathways. This analysis may explain why KMT2D transfected PC12 cells 
exhibited an increased migratory potential, since the TGF-beta pathway as well as the triad 
extracellular matrix, focal adhesion and regulation of actin cytoskeleton are important players 
in mediating migratory potential and invasive properties of various tumor types. 
In summary, we found that somatic KMT2D mutations are frequent in PCCs. Our findings 
highlight a possible novel gene implicated in PCC tumorigenesis, and suggest that 
methyltransferase dysregulation could constitute a novel pathogenic mechanism for subsets 
of PCC.   
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VI – LACK OF KMT2D MUTATIONS IN PGL  
In study VI (204), we report the screening of PGLs for mutations in the KMT2D gene. The 
study is a continuation of Paper V where somatic KMT2D mutations were reported in 14% of 
PCCs and methyltransferase dysregulation was proposed as a novel disease mechanism in 
this tumor entity. Here we sought to assess whether PGLs display any KMT2D gene 
mutations as well as investigate KMT2D gene expression, copy number alterations and 
lysine-specific histone methylation levels. Thirteen PGLs were included and all exhibited 
KMT2D wild-type sequences only. KMT2D gene expression was found to be significantly 
higher in PGLs than in normal adrenal samples and positive nuclear KMT2D 
immunoreactivity was found in the majority of cases. We could also see a significant 
association between KMT2D protein and positive H3K4me3 staining. Also, subsets of PGLs 
displayed copy number gain of the KMT2D locus. In summary, our data suggest that KMT2D 
mutations in PGLs are rare or absent. The finding of deregulated KMT2D expression 
compared to normal adrenals might also suggest an abnormal methyltransferase regulation in 
PGLs, which expands our current notion regarding PGL tumorigenesis and its known 
coupling to histone methylation aberrancies. 
When performing gene expression analysis, an ideal comparison to PCCs would be normal 
adrenal medulla rather than whole adrenal glands as used in Papers I, V and VI since 
adrenocortical tissue is more predominant in the adrenal gland compared to the medullary 
cells. However, due to the miniscule nature of a normal adrenal medulla and the rarity of 
normal adrenal tissues at a whole, these tissue specimens are very hard to obtain. As an effort 
to comply with this problem, we have done two (non-published) serious attempts. In the first, 
we employed a microscopy-guided dissection technique using formalin-fixed paraffin-
embedded (FFPE) material, in which sections of 12 normal adrenal tissues were collected 
from the Karolinska University Hospital biobank, and subsequently dissected to remove 
cortex from medulla. RNA was extracted using an RNA extraction kit specialized for FFPE 
samples, but unfortunately all samples failed the amplification step with qRT-PCR, probably 
due to fragmented material. The second attempt included a macroscopic dissection technique 
in which multiple 1x0.5 mm biopsies were taken directly postoperatively from a normal 
adrenal gland where one part of the biopsy was snap frozen in liquid nitrogen and the other 
part was directly put in formalin and processed as a paraffin block. Representativity slides 
from each block were stained for heamatoxylin-eosin and investigated by an experienced 
endocrine pathologist using light microscopy. Using this technique, a single biopsy proved to 
contain >80% adrenomedullary cells, supported by strong chromogranin A and 
synaptophysin immunostaining, which are neuroendocrine cell markers known to be 
expressed in adrenal medulla. This biopsy was then assessed for KMT2D gene expression by 
qRT-PCR. The results as here presented in Figure 15, show that the normal adrenomedullary 
biopsy exhibited KMT2D expressional levels similar to the normal adrenals.   
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Figure 15.  
KMT2D expression in biopsies from normal adrenal gland. 
The figure shows H&E-stained representativity slides from three biopsies (1, 2 and 3), 
with ChrA and SYP immunohistochemical stainings for biopsy 1 with their relative 
KMT2D gene expression (normalized to biopsy 1 = 1) below.  
 
62 
 
CONCLUDING REMARKS 
 
All six studies included in the thesis show that the genetic and molecular background of 
PPGL is remarkably diverse with a very high degree of heritability and up to date, 25 genes 
(and counting) that are associated with PPGL tumorigenesis to some extent. The work as 
presented in this thesis aimed to further characterize the genetic and molecular background of 
these tumors, and may have contributed to a piece of the PPGL puzzle that together with 
other studies can contribute to better diagnosis, prognosis and treatment for the patients. The 
specific conclusions for the papers are outlined below. 
In Paper I, our results suggest that the VHL gene is inactivated through promoter methylation 
which could trigger PPGL development, a finding that in the future may have implications 
for better prognosis and/or treatment for the PPGL patients.  
In Paper II, a comprehensive NGS mutation screening analysis showed that a large subset of 
the PPGL investigated had mutations in the susceptibility genes. This knowledge is of certain 
importance in order to detect patients that might be in risk as well as facilitate early detection 
of tumors and knowledge of how to treat the different diseases. We were also able to prove 
the usefulness of a fast and cost-efficient sequencing method. 
In Paper III, we concluded that NF1 immunohistochemistry is not a satisfactory screening 
method alone for NF1 mutations and that genetic screening together with clinical workup 
remains the most reliable tool to pinpoint NF1 patients. 
In Paper IV, we found that HRAS mutated PCC cluster together with NF1- and RET-mutated 
tumors and that these mutations are considered to constitute a somatic driver event in benign 
PPGLs without other known susceptibility gene mutations. 
In Paper V, a whole exome sequencing approach was used in order to screen for novel 
susceptibility genes. The KMT2D gene was frequently mutated in PCCs which highlights a 
possible novel gene implicated in the tumor development. As of this, we also suggest that 
methyltransferase dysregulation could represent a novel pathogenic mechanism in the tumors. 
In Paper VI, we screened PGLs for mutations in the KMT2D gene due to the findings in 
Paper V and the similitude of PGLs and PCCs. All PGLs showed wild-type sequences of the 
KMT2D gene and we therefore concluded that mutations in this gene are rare or absent in 
PGL. 
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